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ABSTRACT 
 
ENZO PALMA: Antibody-mediated Systemic Delivery of CpG Oligodeoxynucleotides 
for Solid Tumor Immunotherapy 
 (Under the direction of M.J. Cho, Ph.D.) 
 
The present investigations focus on the development of an antibody-based (IgG) 
endogenous drug delivery system for the systemic delivery of CpG 
oligodeoxynucleotides (CpG-ODNs) in the immunotherapeutic treatment of solid tumors.  
Four fundamental observations support this research: (i) current CpG-ODN 
immunotherapeutic regimens require frequent intra/peritumoral(local) injections, 
restricting their application to external solid tumors only, (ii) endogenous IgG and 
monomeric immune complexes (1:1 stoichiometry) have a long circulation half-life, slow 
clearance, low volume of tissue distribution, and passively extravasate into the tumor 
periphery via the Enhanced Permeability and Retention (EPR) effect, (iii) the cellular 
targets for CpG-ODN are peritumoral dendritic cells and macrophages, which highly 
express Fc= receptors.  These receptors endocytose IgG and monomeric immune 
complexes via their Fc portion, and (iv) the molecular receptor for CpG-ODN, TLR 9, is 
located inside the endosome.  To this end, the binding affinity of model ODNs to anti-
dinitrophenyl (DNP) IgG was optimized through the strategic derivatization of DNP 
epitopes (Chapter II).  The premise behind this study was to obtain the highest affinity 
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complex between DNP-ODNs and anti-DNP IgG, as to prevent ODN systemic 
dissociation.  Accordingly, the chosen bivalent design yielded a 66-fold enhancement in 
binding affinity and was used to derivatize CpG-ODNs for in vivo studies.   
 
Pharmacokinetic (PK) and biodistribution analysis of bivalent, monovalent, and 
underivatized immunotherapeutic CpG oligodeoxynucleotides in a DNP-immunized, 
syngeneic tumor-bearing mouse model ensued (Chapter III). The prolonged half-life, 
reduced volume of distribution, slowed systemic clearance, and enhanced tumor 
accumulation observed during this investigation for both monovalent and bivalent DNP-
CpG-ODNs warranted further pharmacodynamic studies (Chapter IV).  In this case, 
however, only the monovalent conjugate was tested for its ability to inhibit tumor growth 
in the same animal model.  Its physiological effect was also assessed through gross 
physiological observation and histological analysis of lymphoid organs (liver and spleen) 
and solid tumors.  As expected, the systemic disposition profile of DNP-CpG-ODN 
observed during PK studies correlated to an enhanced therapeutic efficacy as this 
formulation inhibited the growth of solid tumors and elicited necrosis of tumoral tissue.  
All together, these findings attest to the validity of this drug delivery approach for the 
targeted systemic immunotherapeutic treatment of solid tumors. 
 
.
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CHAPTER I 
 
INTRODUCTION 
 
This chapter is based on the following submitted manuscript: 
Palma E. and Cho M.J. Systemic Drug Delivery with Endogenous IgG Antibodies. 
Cellular and Molecular Life Sciences (2006). 
2PREFACE 
 
This introductory chapter applies to the general application of endogenous IgG 
antibodies for systemic drug delivery.  A number of therapeutic applications are 
discussed, however, the present dissertation research only concerns itself with the use of 
endogenous IgG for the systemic delivery of CpG oligodeoxynucleotides to solid tumors 
(also discussed).  Other potential applications were included to highlight the wide range 
of applicability of the technology presented herein. 
3Abstract 
Systemic drug administration affords complete and indiscriminate tissue 
accessibility, increasing the probability for drug deposition not only on tissues of 
therapeutic interest but also on clearance-mediating organs.  Targeted drug delivery 
systems (DDS) lessen such probability by preventing drug accumulation at 
therapeutically irrelevant tissue and fomenting its deposition at target sites.  Because 
most delivery systems are synthesized and formulated exogenously, immunogenicity 
becomes a serious problem often limiting their repeated applicability.  The use of an 
endogenously assembled DDS could mend this problem.  The present review provides a 
detailed overview on the applicability of endogenous anti-hapten antibodies, elicited 
through active immunization, as systemic delivery systems for hapten-conjugated drugs.  
Antibody-drug immune complex (IC) pharmacokinetics (PK), tissue distribution, passive 
and active targeting strategies, and potential therapeutic applications are discussed. 
 
Introduction 
Intravenous (IV) drug administration renders a drug 100% bioavailable, ensuring 
its full systemic absorption and maximizing its extent of tissue exposure.  Target tissue 
uptake and drug accumulation, however, ultimately depend on a drug’s ability to avoid 
interactions with clearance-mediating organs, such as the liver and the kidney, and to 
promote high affinity interactions with the tissue of interest.  To achieve this, DDS are 
often employed during IV drug formulation. 
 
4Chemical conjugation, encapsulation, or complexation of a drug to a systemic 
delivery system dramatically affects its systemic behavior, changing its PK as well as its 
tissue distribution profile (Dhanikula et al., 2005; Lee et al., 2005; Vicent et al., 2006).  
Depending on the drug’s pharmacological application, a DDS can work to prolong the 
drug’s circulation half-life, curb its systemic clearance, minimize its volume of tissue 
distribution, and enhance its local accumulation at a targeted tissue.  With this in mind, a 
variety of synthetic DDS, ranging from lipid vesicles and particles to viral vectors, have 
been formulated and optimized for IV administration (Cattel et al., 2003; l-Aneed, 2004).  
Although promising results have been attained in many instances, their development is 
usually hampered by their inherent immunogenicity (ability to trigger immune 
recognition and clearance); needless to say, this limits their long-term applicability. 
 
A diversity of strategies has been implemented to address this setback; however, 
complete immunological tolerance of synthetic or exogenous DDS is yet to be achieved.  
In light of this, the use of an endogenous, non-immunogenic molecule represents an 
attractive alternative.  As such, the present review provides a detailed overview on 
structure-function relationships, PK, tissue distribution, and active and passive targeting 
characteristics of endogenous IgG antibodies.  Their potential application in the treatment 
of neoplastic, inflammatory, and infectious diseases is also discussed; excluded is 
however their classical application as targeting vectors for cytotoxic agents (antibody-
drug conjugates) since the treatment of this subject is beyond the scope of this review.  
 
5IgG Structure-function Relationships 
IgG antibodies are high molecular weight (MW=150 kDa) serum glycoproteins 
with long circulatory half-life (t1/2 > 21 days in humans), low volume of tissue 
distribution, and high serum concentration (~12 mg/ml). They are produced and secreted 
by plasma cells as part of the humoral immune response to a specific antigenic insult.  
Structurally, these glycoproteins have a distinct “Y” shape with two different functional 
motifs that enable high-affinity binding and clearance of a circulating antigen.  At the 
fork ends, the two complementary determining regions (CDRs) recognize and bind 
multivalent antigens in molar excess, effecting the formation of high-affinity polymeric 
ICs (see Figure 1).  Coordinately, at the other end of IgG, the Fc region mediates IC 
binding to Fc= receptor (Fc=R)-expressing antigen presenting cells (APCs) and 
phagocytes of the reticuloendothelial system (RES), receptor cross-linking, endocytic 
internalization, and eventual antigen degradation and/or major histocompatibility 
complex (MHC)-mediated antigen presentation.  As such, IgG antibodies are the key 
mediators of humoral immunity. 
 
Monovalent antigens are similarly recognized and bound through the CDRs to 
form monomeric ICs (one IgG per IC).  Because these complexes only include one IgG 
molecule, they are considered structurally similar to monomeric IgG and thus are 
processed by Fc receptors (FcRs) and Brambell receptors (FcRB) accordingly.  Both of 
these receptors, expressed predominantly by APCs and vascular endothelial cells 
respectively, are principally responsible for the constitutive recycling of monomeric IgG 
6and monomeric ICs (Harrison et al., 1994; Junghans and Anderson, 1996; Junghans, 
1997; Mellman et al., 1984). 
 
The FcRB recycling pathway begins with non-specific fluid phase endocytosis at 
the cell surface (see Figure 2, panel A).  Although endosomal FcRB is present at this 
juncture, receptor binding does not occur in the neutral pH of the extracellular milieu 
contained in the early endosomes.  Mild acidification, due to endosomal maturation, 
triggers binding of IgG to FcRB receptors via its Fc region.  At this point, sorting takes 
place: unbound IgG and monomeric ICs follow a degradative lysosomal pathway 
whereas bound molecules are routed back to the cell surface for release upon exposure to 
the neutral extracellular pH (Junghans, 1997; Lencer and Blumberg, 2005).  This process 
results in the catabolic protection of monomeric IgG and monomeric ICs with a half-life 
of 3.8 days and 1.7 days, respectively (Junghans and Anderson, 1996).  Conversely, this 
accounts for the long circulatory half-life of monomeric IgG and presumably of 
monomeric ICs.   
 
FcRI, the high-affinity monomeric IgG Fc receptor, has been shown to rapidly 
recycle monomeric IgG (Harrison et al., 1994; Guyre et al., 2001).  This results from the 
inability of monomeric IgG to cross-link cell-surface FcRI and to trigger, after endocytic 
internalization, lysosomal degradation.  Instead, endocytosed FcRI – IgG complexes are 
routed to the cell surface via pre-lysosomal compartment (Harrison et al., 1994; Mellman 
et al., 1984).  This process, unlike the FcRB recycling pathway, begins with specific 
receptor binding, but proceeds in a similar manner (Figure 2B).  In the case of 
7monomeric ICs, it is presumed that due their single valence (one Fc domain) are subject, 
to some extent, to the same recycling mechanism. 
 
Tissue Distribution and Systemic Clearance  
At steady state, IgG antibodies are known to reside in the vascular space and in 
the tissue interstitium, however, at much lower concentrations (Lobo et al., 2004).  Tissue 
concentrations depend on the extent of IgG extravasation via paracellular passage across 
the vascular endothelium and its accumulation in tissue.  However, due to their large 
MW, these molecules can only access such space through convective transport (down the 
blood-tissue hydrostatic gradient) or via active uptake mechanisms such as FcRB 
recycling pathway and Fc=R-mediated endocytosis.  Since convective blood-to-tissue 
transport is efficiently counteracted by convective tissue-to-blood transport provided by 
the lymphatic system, this mechanism of tissue accumulation is considered minor in 
comparison to receptor-mediated processes.  Thus, IgG accumulation is mainly restricted 
to tissues expressing high density of FcRB or Fc=R, i.e. liver and spleen (Gessner et al.,
1998).    
 
IgG clearance is also greatly influenced by the large MW of these glycoproteins.  
IgG antibodies are thus not subject to renal excretion and rely solely on the constant 
catabolic sorting provided by FcRB receptors (see Table 1).  As discussed previously, 
this mechanism works to protect viable monomeric IgG from degradation while 
promoting proteolysis of damaged, non-functional, or excess IgG (Ghetie and Ward, 
2002).  Consequently, IgG exhibits a long circulation half-life, with slow catabolic 
8clearance, and a volume of tissue distribution at steady state that closely resembles that of 
the plasma volume.  Collectively, these PK characteristics make IgG an ideal endogenous 
systemic DDS. 
 
Drug Delivery Strategies 
The key to utilizing IgG as an endogenous systemic DDS relies on, (i) attaining a 
high systemic molar excess of hapten-specific IgG with respect to its ligand (drug) as to 
promote complete systemic binding, and (ii) derivatizing the drug of interest with only 
one hapten molecule such that the only possible molecular complex in circulation are 
monomeric IC.  This strategy has been reduced to practice by a number of investigators 
trying to improve the PK and biodistribution of intravenously administered IL-6 
(Montero-Julian et al., 1995; Marten et al., 1993), IL-2 (Courtney et al., 1993; Sato et al.,
1994), IL-3 (Jones and Ziltener, 1993), IFN-V (Rosenblum et al., 1985) and digoxin 
(Renard et al., 1999).  However, in all of these instances, all of the ligands were 
complexed ex vivo to anti-ligand monoclonal IgG (2-1000 fold molar excess) prior to 
their IV administration.  Although the results were promising, potential issues with 
respect to the formulation of IgG at high concentrations, IC in vivo stability, and the 
shorter half-life and immunogenicity of monoclonal IgG provided an opportunity to 
improve this novel approach to systemic drug delivery.  To this end, our laboratory has 
investigated the use of endogenous polyclonal anti-hapten IgG as an endogenous 
systemic drug carrier for PK-challenged small molecular drugs, oligodeoxynucleotides, 
and peptides.  This approach was taken to resolve ex vivo formulation issues, avoid the 
inherent immunogenicity of monoclonals, and maximize antibody circulation half-life. 
9With this in mind, Rehlaender and Cho (2001a and b) investigated the influence 
of titer, binding affinity, and ligand molecular weight on the PK of monofluoresceinated 
ligands in FITC-immunized mice.  Blood concentration vs. time profiles of 
fluoresceinated ethanolamine (FL-EA) in mock-immunized, low-titer, high-titer, and very 
high-titer mice revealed the importance of stoichiometry in IC formation, highlighting the 
need of a high molar excess of IgG (with respect to ligand) for maximal prolongation of 
ligand half-life (see Figure 3, panel A).  Similarly, this investigation highlighted the 
importance of ligand binding affinity in IC in vivo stability since FL-EA injected into 
eosin-Y-immunized mice (a lower-affinity structural analogue of fluorescein) failed to 
exhibit the extent of half-life prolongation observed in FITC-immunized mice (results not 
shown). 
 
The effect of ligand MW was also tested in high titer, FITC-immunized mice.  In 
this case, IgG light chain (FL-LC, MW=25 kDa) and half-light chain (FL-LC1/2, MW=11 
kDa) were tested against the low MW ligand FL-EA (MW = 450 Da) over the course of 
72 hours (see Figure 3, panel B).  Expectedly, blood ligand concentration decreased with 
time as a function of increasing ligand MW however, such effect was attributed to the 
decreased antibody binding affinity exhibited by high-MW ligands and not directly to the 
physical increase in MW.  Collectively, these studies reveal the importance of hapten-
specific IgG titer and antibody binding affinity on the PK of monohaptenated ligands 
(also see O’Hear and Foote, 2005) 
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In line with these studies, it was decided to further optimize this delivery strategy 
by investigating methods of enhancing antibody binding affinity, namely by varying our 
ligand structural design (27-mer oligodeoxynucleotide) with respect to antigenic valence, 
epitope density, inter-epitope linker length, and linker flexibility (Palma et al., 2005).  
Single structural variations resulted in modest increases in binding affinity however, 
collectively, these structural modifications resulted in a 66-fold increase in binding 
affinity while keeping the IC in a monomeric state.  Eventual PK evaluation of this 
affinity-enhanced ligand and a monovalent control in an immunized mouse model 
showed a dramatic improvement in PK but no significant differences in blood ligand 
concentration levels between the tested groups, perhaps indicating that a 66-fold increase 
in binding affinity is not significant in vivo (results not shown). 
 
The application of monoclonal IgG antibodies in classical drug delivery has 
always centered on the exquisite specificity of this protein for its target and its potential 
applicability in targeting antibody-conjugated cytotoxic agents.   Recent interest on the 
PK properties of monoclonal IgG has generated much inquisitive research with respect to 
its use as a drug carrier for the improvement of drug PK (Rehlaender and Cho, 1998).  
However, inherent immunogenicity and ex vivo formulation requirements have prompted 
us to investigate the applicability of endogenous polyclonal IgG as a drug carrier.  Due to 
its endogenous origin, polyclonal IgG not only lacks immunogenicity but it also exhibits 
a longer systemic half-life than its monoclonal counterpart, making it an ideal candidate 
as a systemic drug carrier.  Moreover, the generation of high titers of endogenous hapten-
11
specific IgG can easily be achieved through routine active immunization, to which a 
mono-haptenated ligand can be complexed in vivo after IV administration.  
 
Active Immunization  
The in vivo synthesis and secretion of endogenous, antigen-specific IgG 
antibodies can be routinely be achieved through active immunization.  To this end, 
multiple copies of a choice antigen are coupled to a large, immunogenic carrier protein 
such as keyhole limpet hemocyanin and administered intraperitoneally, subcutaneously, 
or intradermally in conjunction with an adjuvant.  Primary and secondary injections of 
this emulsified formulation are spaced two to three weeks apart in order to achieve, at the 
end of a seven week period, a high level of antigen-specific IgG that persists in the 
circulation for months and in some cases for years.  Antigen-specific IgG titers can be 
monitored throughout this process by subjecting serum samples to an antigen-specific 
enzyme linked immunosorbent assay (ELISA).  Due to the routine nature of these 
procedures, protocols detailing choice of antigen, antigen concentration, carrier protein, 
type of adjuvant, vaccine formulation parameters, and route of administration have been 
validated for a number of laboratory animals. 
 
IgG antibodies generated through active immunization are polyclonal in nature 
and display a wide range of binding affinities (Janeway, 2001).  Although this could 
adversely affect the extent of drug binding in the systemic circulation, active 
immunization protocols are designed to elicit the production of high levels of 
endogenous, antigen-specific IgG, in high molar excess relative to the antigen.  As 
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dictated by the law of mass action, this stoichiometric excess favors monomeric IC 
formation and ensures that the targeted drug is fully bound to IgG while in the systemic 
circulation. 
 
Because the timeline of active immunization could be incompatible with the 
progression timeline of some diseases, immunization schedules must be carefully planned 
to match the targeted disease.  For example, diseases that require acute intervention can 
take advantage of this technology by taking a prophylactic approach.  In other words, 
hapten immunization would take place prior to disease manifestation, in this way, when 
pathogenesis sets in, therapeutic treatment would only require a booster injection of 
antigenic hapten to attain high levels of anti-hapten IgG in a short period of time.  On the 
other hand, if the disease does not require such an aggressive approach, routine active 
immunization could be applied post-disease manifestation.  Alternatively, the use of 
common haptens against which immunity has already been elicited through either 
childhood vaccination or through evolutionary selection (galactosyl-epitope) could also 
be implemented (Galili, 2005). 
 
Hapten Selection and Drug Derivatization 
The selection of a suitable hapten for immunization and drug derivatization must 
take into consideration its immunogenicity and relative ease of chemical conjugation.  As 
such, small hydrophobic organic compounds such as 2,4-dinitrophenyl (DNP) or 
fluorescein have been extensively used to generate high levels of anti-DNP or anti-
fluorescein IgG (Lu et al., 2005; Palma et al., 2005; Rehlaender and Cho, 2001 a and b).  
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Chemical conjugation of these compounds to KLH (multiple derivatization) or to a 
therapeutic molecule (mono-derivatization), can easily be achieved by using 
commercially available synthons such as dinitrobenzenesulfonic acid or fluorescein 
isothiocyanate (FITC).  In the case of KLH, conjugation is usually directed to 
nucleophilic epsilon-amine groups present in multiple lysine residues.  In the case of drug 
molecules, conjugation chemistry depends on the type of available functional groups for 
derivatization (Hermanson, 1996) 
 
Drug haptenation must occur in a controlled manner and should only be directed 
to a single functional moiety such as an amine, alcohol, or carboxylic acid, since the 
derivatization of multiple haptens could mediate the formation of polymeric ICs.  
Furthermore, the pharmacological activity of such drug must not be adversely affected by 
hapten derivatization.  Bearing this in mind, only drugs displaying single functionalities 
or amenable to mono-derivatization can be considered for IgG-mediated systemic drug 
delivery.  This may include small molecular weight drugs as well as 
oligodeoxynucleotide and peptidyl drugs but excludes globular proteins due to their 
multiple expression of functional groups.  In the case of oligodeoxynucleotide (ODN) 
and peptide-based drugs, DNP-monoderivatization can conveniently be accomplished 
during the automated solid phase synthesis of these molecules by using commercially 
available DNP-phosphoramidite and DNP-lysine synthons, respectively. 
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Passive IC Targeting 
Once a haptenated ligand is complexed in the systemic circulation, it can exploit 
the passive targeting properties inherent to IgG.  Monomeric ICs take advantage of their 
large MW and long circulation half-life to passively, but preferentially, extravasate 
through the large intercellular gaps found in the vascular endothelium associated with the 
liver and the spleen, as well as, with rapidly growing solid tumors (Ishida et al., 1999;
Maeda et al., 2000; Yokomori et al., 2003).  Endothelial gaps in hepatic and splenic 
vascular endothelium increase blood exposure in these organs, thereby facilitating their 
blood filtering function.  In tumor tissue, however, endothelial gaps result from the 
uncontrollable and chaotic neovascularization required to support typical rapid tumor 
growth (Jain, 2002). 
 
Under normal physiological conditions, i.e. in the liver and spleen, increased 
vascular permeability and macromolecular influx result in increased interstitial fluid 
pressure (IFP).  The lymphatic system counters such an increase in IFP by convectively 
returning macromolecules that do not exhibit tissue/cellular affinity back to the systemic 
circulation.  In a pathophysiological setting, i.e. in solid tumors, macromolecular 
extravasation also results in increased IFP.  In this case, however, because tumor-
associated lymphatics are present but largely non-functional, pressure increases are not 
offset by lymphatic macromolecular clearance (Padera et al., 2002).  Instead, they result 
in the preferential accumulation and retention of macromolecules in the tumor periphery, 
a phenomenon known as the Enhanced Permeability and Retention (EPR) effect (see 
Figure 4; Maeda et al., 2000) 
15
Likewise, elevated IFP also poses a physical barrier to macromolecular transport 
through the tumor interstitium and therefore limits the site of macromolecular 
accumulation to the tumor periphery (Jain, 1998).  Moreover, accumulation only appears 
to be transient and macromolecules ultimately require tissue or cellular affinity to be 
retained within the tumor interstitium (Berk et al., 1997).  As a result, tumor-targeted 
EPR-based DDS must incorporate an active targeting moiety that exhibits tumor tissue or 
cellular binding affinity. 
 
Similar to tumorigenesis, inflammation is also a pathophysiological condition that 
displays increased macromolecular vascular permeability and therefore, can be passively 
targeted by monomeric ICs via the EPR effect (Bogatcheva et al., 2005).  Inflammation, 
however, does not deleteriously affect lymphatic function and passively accumulated 
macromolecules that do not display tissue affinity are subject to lymphatic clearance.  It 
is therefore apparent that although EPR-based drug delivery represents an effective way 
to deliver macromolecular drugs to an organ/tissue with high vascular permeability, 
tissue or cellular affinity is imperatively required to achieve macromolecular tissue 
retention and to achieve a high local therapeutic drug concentration. The following 
section delves into such topic. 
 
Active IC Targeting 
Fc= receptors, specific for the Fc portion of IgG, have evolved to mediate a 
myriad of processes that bridge humoral and cellular immunity.  One such process is the 
endocytic uptake of polymeric ICs by phagocytes for lysosomal degradation and, if 
16
applicable, subsequent antigen presentation.  Fc=Rs are classified into three classes based 
on their binding affinity for the different subclasses of IgG.  Only one class, however, 
Fc=RI, is capable of binding monomeric IgG and monomeric ICs.  Accordingly, Fc=RI 
represents the main molecular target for monomeric ICs and the cells in which it is 
expressed, namely antigen presenting cells (APCs) and the phagocytes of the RES, their 
cellular target (Gessner et al., 1998). 
 
At the tissue level, mononuclear phagocytes of the RES, as well as professional 
APCs, such as dendritic cells (DCs) and macrophages, are associated with the liver, 
spleen, and sites of inflammation (Janeway, 2001).  DCs and macrophages, in particular, 
are also known to populate the periphery of solid tumors in response to tumorigenesis 
(Ochsenbein, 2002).  Needless to say, this situation is ideal for monomeric IC–mediated 
drug delivery since actively-targeted Fc=RI-expressing cells are conveniently located at 
the site of IC extravasation.  Fc=R-bound monomeric ICs, however, are efficiently 
internalized into an endosome.  Because dissociated ligands are completely sequestered 
within the endosomal compartment and do not gain access to the cytosol, only endosome-
active drugs can be amenable to this technology.  The next section discusses the 
therapeutic applications of such agents.   
 
Therapeutic Applications 
Monomeric ICs display a wide range of therapeutic applicability by improving 
systemic PK and delivering therapeutics specifically to RES phagocytes or tissue APCs.  
Their ability to sequentially target sites of increased vascular permeability and the 
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phagocytes that reside in them could be potentially used in the therapeutic treatment of 
neoplastic, auto-inflammatory, or infectious disease.  As such, monomeric ICs offer an 
attractive alternative to exogenously-formulated synthetic drug carriers in the delivery of 
phagocyte-targeted, endosome-active therapeutic agents. 
 
Neoplastic Disease
One of the many defense mechanisms displayed by tumor cells to avoid immune 
recognition and attack is the secretion of immunosuppressive cytokines that render 
tumor-associated macrophages (TAMS) and peritumoral DCs immunologically dormant 
(Ochsenbein, 2002).  This state of dormancy affects their ability to efficiently present 
ingested tumor antigen and establish a subsequent anti-tumor immunity.  Accordingly, 
immunostimulatory agents have been tested for their potential to activate DCs for antigen 
presentation; one of such agents is CpG-oligodeoxynucleotides (CpG-ODNs; Weiner, 
2000). 
 
CpG-ODNs are short oligodeoxynucleotides (18-22-mer) that, depending on their 
particular sequence, stimulate the activity of DCs, macrophages, B cells, and NK cells.  
Their sequence, as their name implies, features the potent immune-stimulatory 
unmethylated cytosine-guanosine dinucleotide (CpG), a motif that alerts immune cells of 
pathogenic danger.  This is mediated by the Toll-like receptor 9 (TLR9), located inside 
the phagocytic endosomes.  The engaging of such a receptor results in the transcriptional 
activation of pro-inflammatory cytokine genes required for a coordinated APC and T-cell 
anti-tumor immune response (Krieg et al., 2000). 
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Therapeutic application of CpG-ODNs in the treatment of solid tumors, however, 
requires sustained, site-specific activation of peritumoral APCs, an effect currently 
achieved only through frequent peri/intratumoral injections (Heckelsmiller et al, 2002).  
Unfortunately, this localized approach dramatically restricts the therapeutic applicability 
of CpG-ODNs to superficial or external tumors, a minor fraction of all tumors.   Systemic 
delivery can address this problem by making internal solid tumors accesible; however, 
due to their rapid systemic clearance, CpG-ODNs would require a DDS.  To this end, 
Whitmore et al. (2001) formulated CpG-ODNs into a lipid-protamine-DNA (LPD) 
particle prior to their systemic administration into a mouse lung tumor model.  Dramatic 
reduction in lung tumor burden was observed with this formulation as compared to 
controls, a result that attests the validity of this approach. 
 
On the same note, CpG-ODNs-IgG monomeric ICs could be used to passively 
and actively target CpG-ODNs to the tumor site after their systemic administration.  In 
fact, our laboratory has tested this approach by derivatizing DNP to the 3’ end of CpG-
ODN and administering these agents intravenously in a DNP-immunized, tumor mouse 
model.  Apart from achieving prolongation of systemic half-life and slowed clearance, 
sizable tumor accumulation was attained.  Correspondingly, tumor volumes were 
decreased and tumor necrosis was significantly enhanced (results not shown).  Although 
these preliminary results yield great promise, a number of immunological studies must be 
conducted to better understand the pharmacological mechanisms behind CpG-monomeric 
ICs anti-tumor activity. 
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In an alternative approach, monomeric ICs could also be used to deliver antigenic 
peptides coding for tumor antigens to peritumoral DCs and macrophages.  This 
therapeutic vaccine approach is somewhat similar, in terms of drug delivery, to the 
immunotherapeutic strategy mentioned above, however, one distinct advantage with 
regard to antigen presentation should be highlighted.  Traditionally, APC-processed 
antigens are restricted to one of two different major MHC presentation pathways (MHC 
class I or II).  Presentation of exogenous antigens to CD4+ T cells (T helper cells) is 
relegated to the MHC class II pathway; endogenous antigens, on the other hand, are 
presented via the MHC class I pathway to CD8+ T cells (CTLs).  Antigenic ICs, in 
contrast, can trigger the presentation of antigen via both pathways, a phenomenon known 
as cross-presentation (Regnault et al., 1999).  Because such a process results in the 
priming of T helper cells and CTLs, a more potent anti-tumor response results (Rafiq et 
al., 2002).  Lastly, combination therapy, using antigenic peptides and CpG-ODNs could 
also prove valuable. 
 
Inflammatory Disease
Rheumatoid arthritis (RA) is an inflammatory autoimmune disorder characterized 
by chronic joint inflammation.  Two major local events occur during arthritic 
pathogenesis: an increase in vascular permeability and the abnormal activation and 
proliferation of joint macrophages leading to the secretion of pro-inflammatory 
cytokines, such as TNF-V, IL-6, and IL-12.  These cytokines direct the formation and 
activation of osteoclasts, which play a central role in disease progression (Firestein, 
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2005).  Accordingly, suppressing cytokine secretion by joint macrophages represents a 
viable therapeutic approach against RA. 
 
The systemic targeting of immunosuppressive agents to arthritic joints could 
potentially be accomplished with monomeric ICs. The proposed immunotherapeutic 
approach is similar to the one taken for solid tumors since these two conditions share 
similar pathophysiologies and cellular targets.  However, in this case, the goal is to 
suppress activated macrophages than to activate suppressed macrophages.  To this end, a 
different endosome-active TLR 9 ligand, inhibitory CpG-ODNs, could be used to 
counteract the secretion of inflammatory cytokines by activated macrophages.  These 
phosphorothioate oligodeoxynucleotides are the immunological antagonists of CpG-
ODNs, as they efficiently suppress the immune activation elicited by CpG-ODNs 
(Duramad et al., 2005). 
 
Monomeric ICs loaded with inhibitory CpG-ODNs could also be used to target 
other inflammatory diseases that require macrophage immunosuppression, i.e., 
atherosclerosis and systemic inflammation.  Atherosclerosis is a chronic inflammatory 
condition by which monocytes, attracted to the vascular endothelium, migrate from the 
extravascular space into the subendothelium and differentiate into macrophages and DCs.  
Their subsequent activation and secretion of pro-inflammatory cytokines promotes the 
formation of atherosclerotic plaques and lesions (Charo and Ransohoff, 2006).  Similarly, 
systemic inflammation results in increased systemic concentrations of pro-inflammatory 
cytokines, a fatal condition if gone untreated.   
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Infectious disease
Because RES macrophages play a central role in the pathogenesis of many 
parasitic, viral, and bacterial infections, monomeric ICs can potentially be applied to their 
therapeutic treatment.  For example, visceral leishmaniasis, which affects splenic and 
hepatic macrophages, could be targeted with monomeric ICs loaded with haptenated 
antimony compounds, given that haptenation does not affect pharmacological activity. 
This systemic active targeting strategy could not only potentiate therapeutic activity but it 
could also alleviate the systemic toxicity often observed with anti-protozoan drugs (De 
Carvalho et al., 2003). Alternatively, CpG-ODNs have successfully been used to target 
this disease (Vanloubbeeck and Jones, 2004) 
 
Conclusions 
IgG antibodies have traditionally been used for their exquisite tissue targeting 
abilities to deliver drugs to a specific tissue (antibody-drug conjugates) or to specifically 
label antigens for immunological clearance.  Their favorable PK and passive targeting 
abilities, however, have been applied to a limited extent. Accordingly, their application as 
systemic DDS represents a novel approach to drug delivery. 
 
ICs composed of only one IgG molecule, i.e. monomeric ICs, are able to evade 
immunological clearance due to their molecular similarity to monomeric IgG, a long- 
lived, high MW serum glycoprotein.  As such, monomeric ICs exhibit the optimal PK 
characteristics that are intrinsic to monomeric IgG namely, long circulation half-life, slow 
clearance, and low volume of distribution.  The combination of long circulation half-life 
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and high MW grants monomeric ICs with the ability to extravasate into tissues that 
exhibit high vascular permeability.  This ability can be exploited to passively target drug-
loaded monomeric ICs to the liver, spleen, solid tumors, and inflammation, all 
distinctively permeable to macromolecules. 
 
Extravasation alone, however, does not guarantee retention at these sites since 
tissue-extravasated macromolecules are routinely returned to the circulation by the 
lymphatic system or in the case of solid tumors, macromolecules are returned to the 
circulation as a result of the high intratumoral IFP.  Tissue retention is thus attained by 
the active uptake of these complexes by Fc=R-expressing cells that reside in these target 
tissues, namely RES phagocytes and APCs.  Cellular uptake sequesters monomeric ICs in 
phagocytic endosomes, making these compartments their subcellular destination.  As 
such, monomeric ICs can be used to deliver endosome-active drugs to Fc=R-expressing 
phagocytes residing in the liver, spleen, solid tumors, or inflammation sites to stimulate, 
suppress, or terminate their activity.  This immunotherapeutic approach could prove 
beneficial in the treatment of diseases that adversely affect the normal activity of resident 
macrophages, as is the case in neoplastic, inflammatory, or infectious disease.   
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Figure 1. Structure-function relationships of an IgG antibody.
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Figure 2. Schematic representation of IgG molecular recycling mechanisms. A. The Brambell (FcRB) receptor pathway: monomeric
IgG and monomeric ICs are internalized via non-specific endocytosis (1) and sequestered inside an endosome (2). Mild endosomal
acidification (3) triggers FcRB binding and the formation of a sorting endosome (4a) which routes receptor-bound ligands back to the
cell surface (5) and released upon interacting with the neutral extracellular pH. Unbound ligands are degraded in the acidic lysosome
(4b). B. The Fc=RI pathway: monomeric IgG and monomeric ICs are internalized via Fc=RI-mediated endocytosis (1 and 2).
Endosomal acidification (3) triggers partial dissociation of antibody-bound ligands which are subsequently degraded by lysosomes
(4b). Bound monomeric IgG and, presumably, monomeric ICs get recycled to the cell surface and released by a poorly understood
mechanism (5).
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Table 1. Clearance and protection mechanisms for IgG, monomeric and polymeric ICs.
IgG monomeric IC polymeric IC
Renal clearance - - -
Fc-mediated - + +++Hepatic and splenic
clearance Complement-
mediated - - ++++
FcRB recycling
(protection from lysosomal
degradation*)
++++ +++ -
*Catabolic t1/2: IgG = 3.78 days, monomeric IC = 1.7 days (Junghans and Anderson, 1996).25
26
Figure 3. Effect of total IgG titer (A) and ligand molecular weight (B) on the serum pharmacokinetics of fluoresceinated
ethanolamine (FL-EA), fluoresceinated half IgG light chain (FL-(LC)1/2), and fluoresceinated IgG light chain (FL-LC) in anti-
fluorescein immunized mice. Reprinted with the permission of the publisher (Rehlaender and Cho 2001 a and b).
26
27
Figure 4. The EPR effect and macromolecular transport barriers in monomeric IC-
mediated drug delivery to solid tumors.  Chaotic vascularization and aggressive growth 
result in large gaps in tumoral vascular endothelium which are permeable to monomeric 
ICs (1); by contrast normal epithelium does not exhibit such macromolecular 
permeability (2).  Once extravasated, monomeric ICs encounter the tumoral interstitium 
which, by virtue of its high collagen content (3), it is considered impermeant to 
macromolecules.  High interstitial pressure (4) resulting from non-functional tumoral 
lymphatics (5) also affects monomeric IC transport through the tumor interstitium; 
consequently, monomeric ICs are retained in peritumoral areas.  Peritumoral resident 
APCs, which are found in greater quantities in solid tumors (6) than in normal tissue (7), 
internalize retained monomeric ICs via Fc=R-mediated endocytosis (8). 
CHAPTER II 
OLIGODEOXYNUCLEOTIDE DESIGN OPTIMIZATION AND 
CALORIMETRIC CHARACTERIZATION OF BINDING AFFINITY 
This chapter is based on the following original publication: 
Palma E., Klapper D.G and Cho M.J. Antibodies as Drug Carriers III: Design of 
Oligonucleotides with Enhanced Binding Affinity for Immunoglobulin G. Pharm. Res.
2005: 22(1) 122-127. 
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Abstract 
Purpose. To understand the structural requirements in designing epitope-bearing 
oligodeoxynucleotides with high antibody-binding affinity.   
Methods. Binding affinity (KA) and stoichiometry (n) of dinitrophenyl (DNP)-
derivatized model 27-mer oligodeoxynucleotides (ODNs), GGG(AAA)7GGG, to 
monoclonal anti-trinitrophenyl (TNP) antibodies were determined using isothermal 
titration calorimetry (ITC). Structural variations were made in the ODNs to assess the 
effects of antigenic valence, epitope density, inter-epitope linker length, and linker 
flexibility. Binding isotherms were fitted with a single binding-site model to obtain  KA
and n, from which  changes in Gibbs free energy (LGº), entropy (LSº), and enthalpy 
(LHº) were derived. 
Results. As expected, ligands displaying increased epitope density showed 
increases in KA: e.g., KA for (DNP)2-Cys is 3.3-fold greater than that for DNP-Lys. 
Introduction of multiple DNP groups via long and flexible linkers to one end of the 27-
mer ODN resulted in a bivalent behavior with n value of 1. A bivalent ligand, derivatized 
at both ends with a long and flexible linker, failed to form an immune complex when 
hybridized to its antisense strand, presumably due to intercalation of the DNP moiety to 
the double strand. ODNs derivatized with flexible linkers exhibited a higher KA than 
those with a rigid linker. Ligands with flexible inter-epitope linkers measuring distances 
of 110, 60, and 40 Å yielded a 13-, 30-, and 13-fold increases in KA, respectively.  The 
combination of these factors; namely, bivalence, flexible inter-epitope linkers, and 
optimal inter-epitope distance, resulted in an overall 66-fold increase in KA.
Thermodynamic analysis of binding indicates that the formation of high affinity ODN-
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IgG complexes was a spontaneous and exothermic event, characterized by large negative 
LSº, LHº, and LGº values. 
Conclusions. All four strategies tested during this investigation, namely 
bivalence, epitope density, inter-epitope linker flexibility, and optimal inter-epitope 
distance, proved to be useful in improving the binding affinity of DNP-labeled ODNs to 
anti-TNP IgG.  The final ODN design incorporating these strategies will be used in 
testing the systemic pharmacokinetic advantage gained from complexing such ODNs to 
IgG.   
 
1. Introduction 
Antisense and immune-modulating synthetic oligodeoxynucleotides (ODNs) have 
emerged as new therapeutic agents targeted to a variety of malignancies, including cancer 
(Carpentier et al, 2003; Sazani et al., 2003).  Their clinical potential is very promising, 
however, once systemically administered, these compounds face various transport and 
metabolic barriers that compromise their delivery to target tissues.  For example, 
oligodeoxynucleotides invariably suffer from exhibit poor systemic pharmacokinetics 
(mainly short half-life and nucleolytic degradation), which prevent them from fully 
exerting their therapeutic effect (Agrawal et al., 1995; Crooke et al., 1996). In light of 
these challenges, this laboratory has been exploring the possibility of using endogenous 
antibodies as systemic drug carriers for prolonging the systemic t1/2 of ODNs and 
preventing systemic nucleolytic degradation (Burdick and Emlen, 1985).  With this 
approach, we exploit the finding that monomeric immune complexes i.e., complexes in a 
1:1 or 2:1 ligand-to-antibody ratio, can effectively lengthen the apparent t1/2 of the 
31
complexed drug molecule to that of the antibody itself, e.g., 21 days for human IgG1 
(Rehlaender and Cho, 2001a/b).   
 
In our previous studies, mice immunized against fluorescein showed at least a 
100-fold decrease in he initial disappearance rate of fluorescein derivatives of a small 
model drug molecule (Rehlaender and Cho, 2001a) as well as of a model protein of MW 
22 kDa (Rehlaender and Cho, 2001b).  Here, the anti-fluorescein antibodies serve as high 
affinity (KA > 107 M-1) and low capacity drug carriers (two binding sites per IgG 
molecule of MW 150 kDa) (Rehlaender and Cho, 1998).  As expected, the 
pharmacokinetics of these model drug molecules expressing a single epitope fluorescein 
critically depended on antibody titer as well as antigen-binding affinity (Rehlaender and 
Cho, 2001a/b).  However, at a given level of titer, which would be the case for 
endogenous antibodies, the overall pharmacokinetic behavior of these immune complexes 
will predominantly depend on the intrinsic antibody binding affinity constant, KA. As 
such, our approach is distinct from the common use of monoclonal antibodies as drug 
targeting ligands. It is, instead, similar to employing long circulating serum proteins, such 
as albumin, as drug carriers.      
 
Antibody binding naturally occurs with multivalent antigens, resulting in the 
formation of large polymeric, precipitable immune complexes that rapidly clear from the 
systemic circulation (Head et al., 1996; Mannik et al., 1974; Skogh et al., 1983).  To 
avoid this event and attain sustained systemic circulation, two requirements must be met. 
First and foremost, the epitope should be introduced to the ODN in such a way that the 
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antigen-antibody interaction is in a monomeric fashion, i.e., in a 1:1 or 2:1 ligand-to-
antibody ratio. Secondly, the binding affinity as expressed by KA must be high so that 
premature ligand dissociation does not occur while in the systemic circulation 
(Rehlaender and Cho, 2001a).  
 
In an effort to optimize binding affinity, a series of model 2,4-dinitrophenyl 
(DNP)-derivatized ODNs were designed with variations in three major factors involved 
in binding to anti-2,4,6-trinitrophenyl (TNP)-monoclonal IgG1 (mIgG1):  epitope 
valence, flexibility of linker between DNP and ODN, and inter-epitope distance.  
Because IgG is a flexible, bivalent protein, with a distance between its antigen-binding 
sites (Fab) ranging from 4 to 12 nm (Harris et al., 1998; Roux et al., 1997), model ODNs 
were designed to reflect these conditions and tested for their propensity to complex anti-
TNP IgG1 using isothermal titration calorimetry (ITC).  Binding affinity (KA), complex 
stoichiometry (n), and subsequently thermodynamic parameters such as changes in 
enthalpy (LHº), entropy (LSº), and Gibbs free energy (LGº) were derived.  
Pharmacokinetic analysis of these immune complexes will be the subject of future 
studies.  
 
2. Materials and Methods 
2.1. Preparation and Characterization of Anti-TNP mIgG1 Antibodies 
Monoclonal anti-trinitrophenyl (TNP) IgG1 was produced by the UNC 
Lineberger Cancer Center using hybridoma cell line 1B7.11 (ATCC TIB-191).  The 
harvested culture medium was dialyzed extensively (SpectraPor, MW cutoff 100 kDa) 
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against phosphate buffered saline (PBS, pH 7.0) and further purified via protein-G 
affinity column chromatography (Amersham Pharmacia, Piscataway, NJ).  Antibody 
purity was confirmed via SDS-PAGE after extensive dialysis against 10mM, pH 8.0 Tris 
buffer (single band, results not shown). Stock antibody concentrations were estimated 
using the BCA assay (Biorad; Hercules, CA).   
 
2.2. Preparation and Characterization of DNP-labeled Oligodeoxynucleotides 
Model oligodeoxynucleotides (sense, 5’-GGG(AAA)7GGG-3’; antisense, 5’-
CCC(TTT)7CCC-3’) were synthesized and labeled with DNP (sense strands only) by 
Oligos Etc (Wilsonville, OR) and Oswel, Inc. (Southampton, UK) using phosphoramidite 
solid-phase chemistry.  ODNs were purified via reverse-phase DMT-on HPLC and 
PAGE and supplied at a purity of > 90%.  Two types of DNP labels were used:  DNP-
TEG (Glen Research, Sterling, VA) provides a flexible, ethylene glycol-based, 18-atom 
DNP-label that can be introduced multiple times during synthesis, whereas DNP-6C 
(Oswel) is a rigid alkyl DNP label that places the DNP epitope only 6 carbons away from 
the DNA backbone (see Figure 1).  Moreover, SPACER 9, a 12 Å tri(ethylene glycol) 
spacer-phosphoramidite derivative (Glen Research) was introduced between successive 
DNP-TEG linkers during solid phase synthesis (Oligos Etc) to lengthen inter-epitope 
distance, see Figure 1.  For the most part, DNP-labeling occurred at the 5’-
oligodeoxynucleotide terminal and it was reasonably assumed that due to the bilateral 
symmetry displayed by these oligomers (Table 1) that derivatization at the 3’ terminal 
would have yielded a similar DNP-derivative with regard to anti-DNP antibody binding.  
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Monovalent controls, namely DNP-Lys and (DNP)2-Cys, were purchased from Sigma 
(St. Louis, MO). 
 
Sense and antisense strands were dissolved in 1.0 ml of 10mM Tris buffer at pH 
8.0 containing 50mM NaCl and 1mM EDTA (TE buffer) and stock concentrations 
estimated spectrophotometrically [260: 3.15 x 105 M-1cm-1 (sense) and 260: 2.13 x 105 M-
1cm-1 (antisense), estimated using nearest neighbor analysis] (Santa  Lucia et al., 1996).  
Duplexes were formulated by mixing equimolar concentrations of sense and antisense 
ODNs, heating to 90º - 95ºC in a heat block, and cooling to room temperature on the 
benchtop.  Proper hybridization was confirmed via nucleic acid PAGE (Biorad; Hercules, 
CA).  Single stranded antigens were used as supplied by the manufacturers, without 
further processing; see Table 1. 
 
2.3. Isothermal Titration Calorimetry and Thermodynamic Analysis 
Titration was performed at the UNC Macromolecular Interactions Facility using a 
VP-ITC microcalorimeter (Microcal, Inc; Northampton, MA).  All samples were 
degassed and cooled to 20°C prior to analysis.  Analyte concentrations varied according 
to the expected stoichiometry of binding. For the most part, a 20-fold excess of ligand 
was used to compensate for any dilution effects during titration.  Briefly, the titrating 
syringe was filled with the ligand of interest (250 µL, 20 µM) and titrated onto a sample 
cell containing anti-TNP mIgG1 (1.5 ml, 1 µM).  A typical analysis would comprise 25-
30 5-µL injections, spaced 120 seconds apart, at 25°C (Figure 2). Data analysis and 
fitting were performed using the ITC analysis software, Origin 5.0 (Microcal, Inc.).  All 
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calorimetric data was corrected for heats of dilution prior to curve fitting with a single 
binding site model.  Control experiments were conducted with underivatized ODNs with 
no discernable calorimetric interaction. Equilibrium association constants (KA), ligand-to-
antibody binding stoichiometry (n), LHº, and LSº were obtained directly from the ITC 
output, whereas LGº was derived using the following equation:  
LG° = -RT ln KA = LHº - TLSº 
 
3.  Results and Discussion 
3.1. Monovalent Complexation 
As shown in Table 1, three monovalent ligands were tested for their ability to 
complex anti-TNP IgG. This study was carried out primarily to establish a reference point 
in assessing the effect of ligand valence and epitope density on KA. As expected, 
monovalent ligands were complexed in a 2:1 ligand-to-antibody stoichiometric ratio as 
depicted on Figure 3, panel A.  Complexation occurred with KA in the range of 106 - 107
M-1 (Table 1).  In the case of (DNP)2-Cys (ligand II, Table 1), a compound displaying 
two DNP epitopes in close proximity, a complete sequestration of the two closely located 
DNP-moieties inside the Fab binding pocket was expected, as seen with other structurally 
similar compounds (Edmundson et al., 1989a/b). Doubling the epitope density of these 
two small molecules (I vs. II), where the epitope is significant in size relative to the 
whole, resulted in a 3.3-fold enhancement of KA (Table 2).  Such gain is thought to result 
from a large decrease in koff, the complex dissociation rate constant, caused by the 
simultaneous binding of two DNP-epitopes within each Fab (Kulin et al., 2002).  A 
concomitant increase in kon, the association rate constant, is also thought to have occurred 
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since increasing epitope density raises the probability of binding by increasing the local 
effective concentration of binding epitopes.  These two events contribute to a large 
increase in KA; hence, epitope clustering represents a feasible strategy to maximize 
binding affinity.   
 
It is worthy to note that VIII and IX, which display a clustering of DNP epitopes 
on the 5’-terminals, were originally intended to test the effect of epitope density on KA.
As such, these ligands were expected to result in high-affinity monovalent binding to 
anti-TNP IgG with n value of 2.  It was thus surprising to observe that they bound anti-
TNP IgG in a bivalent fashion with n value of 1 (Table 1).  We attribute these findings to 
the length and flexibility of the DNP-TEG linkers present in these ligands (Figure 1). The 
inter-epitope distance is estimated to be 48 Å, effectively creating a bivalent environment 
suitable for binding the antibody in a monomeric fashion (Figure 3, panel B). Here and 
throughout this report, the inter-epitope distance was estimated based on extra- and 
intrapolation of the data on the end-to-end distance of various sizes of poly(ethylene 
glycol) chains (Baird et al., 2003). It was also observed that a 26-fold increase in MW (I 
of MW 348.7 vs. III of MW 8,993.0) resulted in 1.7-fold enhancement of KA (Table 2).  
This finding that the increased MW did not have a deleterious effect on complexation 
was somewhat counter-intuitive in terms of so-called binding orientation hypothesis 
(Rehlaender and Cho, 2001b).  
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3.2. Bivalent Complexation   
Ligand IV represents a prototypical bivalent ODN in which the DNP moieties 
both at the 3’- and 5’-terminals effectively mediate monomeric binding across the DNA 
backbone (Figure 3, panel C).  However, once hybridized to its complementary ODN, the 
resulting double stranded ODN failed to bind IgG (data not shown).  Due to the length 
and flexibility of the DNP-TEG linker used to derivatize this ligand, the DNP epitope can 
loop back and intercalate itself into the ODN backbone.  Such a phenomenon has been 
observed with other structurally related ODN labels (Telser et al., 1989) and it was, in 
our case, supported spectrophotometrically (significant suppression of OD360; data not 
shown).  To resolve this problem and confirm our hypothesis on the intercalation of 
DNP-TEG, ligand V was prepared with a much shorter and rigid DNP-ODN linker 
(DNP-6C, Figure 1).  Such modification proved to be sufficient in preventing DNP-
intercalation and expected binding profiles between anti-TNP IgG and ligand V and its 
hybridized analog VI were clearly observed (Table 2). 
 
As shown on Table 3, bivalent binding effectively increased the overall KA of 
complexation, relative to monovalent ligand III.  A 2.3-fold increase in KA was observed 
in the case of IV, consistent with a 2-fold increase in valence.  In contrast, V and VIII 
exhibited a 29-fold increase in KA compared with III (Table 3).  Such a large increase in 
binding affinity was unexpected, however, it is speculated that these 
oligodeoxynucleotides not only reflect the effect of bivalence but also the effect of inter-
epitope distance and linker flexibility (see below).  Similarly, VII yielded a surprisingly 
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high KA value (66-fold increase), thought to result from the aforementioned additive 
effect and not from individual contributions from bivalence.  
 
The rigidity of the linker bridging the two DNP epitopes also had a direct effect 
on binding affinity.  Hybridization of V to its complimentary strand, which resulted in a 
rigid structure VI (Table 1), had a detrimental effect on binding, manifested by a 7-fold 
reduction in binding affinity (Table 3).  These results confirm that linker flexibility is 
necessary to achieve high affinity binding to IgG, a flexible molecule itself (Harris et al.,
1998; Roux et al., 1997).   
 
Similarly, the distance between DNP epitopes greatly influenced the magnitude of 
KA. Direct comparison of the binding affinities of IV, our prototypical bivalent ODN, to 
that of V, VII, and VIII discerned this effect.  Table 3 displays such relationship: V and 
VIII exhibit a 13-fold increase in binding affinity upon reduction of their inter-epitope 
distance from 137 Å (IV) to 111 Å and 48 Å, respectively.  Ligand VII, which has an 
inter-epitope distance of 60 Å, displays a 29-fold enhancement in binding affinity.   
 
The high degree of dependence of KA on antigenic valence, inter-epitope distance, 
and linker flexibility highlights the importance of considering physical dimensions of the 
antibody when designing its ligands.  Such was the approach taken by Paar et al. (2002) 
and Baird et al. (2003) when testing the Fab-crosslinking ability of a series of ligands 
displaying different degrees of valence, flexibility, and inter-epitope distances. Their 
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results corroborate the dependence of high-affinity antibody binding on inter-epitope 
distance, antigenic valence, and ligand flexibility.  Such are also our findings. 
 
3.3. Multivalent Complexation. 
Ligands X and XI (Table 1) were designed to test the additive effect of bivalence, 
epitope density, and linker flexibility on binding affinity.  These ligands were 
successively derivatized, on both terminals, with three DNP-TEG linkers and 
subsequently tested as such (X) or hybridized to their complimentary strands (XI).  
Unfortunately, as shown on Table 4, the stoichiometry of binding indicated the formation 
of dimeric complexes between these ligands and anti-TNP IgG.  Nevertheless, such 
interaction exhibited enhanced binding affinity, thought to result from the increased 
binding capacity of these ligands. As shown on Table 4, the dimeric binding of XI is 6.5-
fold higher than X. We interpret this observation based on the difference in binding 
patterns involved: Figure 3 panel D and E for XI and X, respectively.  Three observations 
support this analysis:  a) the 6.5-fold enhancement of KA seen with XI, the hybridized 
analogue of X, is not characteristic of a rigid ligand but of a flexible compound, as seen 
with V vs. VI on Table 1), b) a 4.8-fold enhancement in binding affinity was observed 
when comparing X to its structural analogue, IV (Table 4).  It is assumed that due to their 
structural similarity (Table 1), these ligands bind IgG similarly, i.e., across their DNA 
backbone, however, an enhancement in binding affinity is observed due to an increase in 
binding capacity (two vs. one IgG molecules, respectively), and c) similar analysis of 
binding affinities between structural analogues XI and IX (Table 1), the latter known to 
bind IgG across its DNP-TEG linkers (Figure 3, panel B; Table 1), reveal a 3.6-fold 
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enhancement in binding affinity (Table 4).  This again is attributed to the increased 
binding capacity of XI. Although these ligands display enhanced affinity, utilizing two 
antibodies for the systemic transport of one oligodeoxynucleotide is neither energetically 
nor cost efficient.  As seen in this investigation, monomeric ligands can be structurally 
tailored to yield high binding affinities when complexing IgG (VII vs. XI, Table 1) 
without having to implement higher epitope densities or binding capacities. 
 
3.4. Thermodynamic Analysis.  
As shown on Table 1, immune complexation is associated with large negative 
LHº and LGº, both indicative of exothermic and spontaneous reactions.  The observed 
decreasing trend in LSº supports the tighter binding indicated by the increasing trend in 
KA, since a negative change in entropy is characterized in the present case by the loss of 
molecular freedom.  Taken together, these thermodynamic parameters suggest that the 
binding of a bivalent, flexible ODN displaying an optimal inter-epitope distance is an 
event more thermodynamically favored than that of a ligand partially displaying the 
aforementioned characteristics.        
 
It is worthy to note that II, which displays two DNP epitopes in close proximity, 
as shown on Table 1, caused a positive change in entropy, a trend not seen with other 
ligands.  It is speculated that this positive change is caused by a dramatic displacement of 
water molecules within the paratope resulting from the accommodation of two epitopes 
inside the antibody’s binding pocket.  This event is contrasted to the interaction of one 
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epitope per paratope seen with all the other ligands, which exhibit negative entropic 
changes (Table 1).   
 
4.  Conclusions 
The optimal oligodeoxynucleotide design for high-affinity immune complexation 
resembles that of VII.  This ODN is a single stranded, flexible ligand terminally 
displaying two DNP-TEG linkers spaced apart by a 12 Å tri(ethylene glycol) linker, 
SPACER 9.  Its design incorporates three of the four strategies tested during this 
investigation; i.e., bivalence, a flexible inter-epitope linker, and an optimal inter-epitope 
distance (60 Å). Implementation of such characteristics result in a 66-fold increase in 
binding affinity over monovalent ligands (Table 3). It remains to be seen if the high-
affinity binding of an ODN to immunoglobulins, be they naturally occurring endogenous 
antibodies or from active immunization, can provide a circulatory life long enough for 
targeted delivery in vivo.  
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Figure 1. DNP-derivatization reagents.  DNP-TEG is a flexible poly(ethylene glycol)-
based linker approximately 22.5 Å in length; DNP-6C is a rigid six-carbon alkyl DNP 
linker approximately 10 Å in length; SPACER 9 is a flexible tri(ethylene glycol)-based 
spacer incorporated between two DNP-TEG linkers.  Its length is approximately 12 Å. 
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Figure 2. Calorimetric titration of IV (left) and IX (right) with anti-TNP IgG in 10mM 
Tris buffer at pH 8.0.  Briefly, the titrating syringe was filled with the ligand of interest 
(250 µL, 20 µM in 10 mM Tris buffer at pH 8.0) and titrated onto a sample cell 
containing anti-TNP mIgG1 (1.5 ml, 1 µM in 10 mM Tris buffer at pH 8.0).  A typical 
analysis would comprise 25-30 5-µL injections, spaced 120 seconds apart, at 25°C. 
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Figure 3.  Binding models for ODN immune complexation based on binding 
stoichiometry.  A, monovalent complexation (III); B, bivalent complexation (VII-IX); C, 
bivalent complexation (IV-VI); D, multivalent complexation (XI) and E, multivalent 
complexation (X).  The additional third DNP-TEG linker on VIII-XI was omitted from 
panels B, D, and E for clarity purposes. 
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Table 1. Structure of DNP-Ligands and Their Binding Parameters to Monoclonal Mouse Anti-TNP IgG1a
Structure (Conformation)b
Inter-
epitope
distance
(Å)c
KA (M-1) n f Hº(kcal mol-1)
Sº
(cal mol-1 K-1)
Gº
(kcal mol-1)
Monovalent Ligands
I. N-2,4-DNP-D-lysine N/Ae 3.9 x 106 2.0 -11.2 -7.5 -8.9
II. N,S-di(2,4-DNP)-L-cysteine N/A 1.3 x 107 1.8 -4.6 17.0 -9.7
III. DNP-TEG-G3(A3)7G3 (f) N/A 6.5 x 106 1.8 -8.8 1.6 -9.3
Bivalent Ligands
IV. DNP-TEG-G3(A3)7G3-TEG-DNP (f) 137 1.5 x 107 1.0 -14.1 -14.8 -9.7
V. DNP-6C-G3(A3)7G3-6C-DNP (f) 111 1.9 x 108 0.8 -33.9 -75.7 -11.3
VI. DNP-6C-G3(A3)7G3-6C-DNP (r)
C3(T3)7C3 111 2.6 x 10
7 0.8 -33.0 -76.4 -10.2
VII. DNP-TEG-SPACER 9--G3(A3)7G3 (f)
DNP-TEG--| 60 4.3 x 10
8 0.9 -63.3 -172.9 -11.8
VIII.d (DNP-TEG)3-G3(A3)7G3 (f) 48 1.9 x 108 1.1 -31.4 -67.3 -11.3
IX.d (DNP-TEG)3-G3(A3)7G3 (f)
C3(T3)7C3 48 1.3 x 10
8 1.1 -29.2 -60.5 -11.2
Multivalent Ligands
X. (DNP-TEG)3-G3(A3)7G3-(DNP-TEG)3 (f) 137 7.2 x 107 0.6 -65.0 -181.9 -10.8
XI.d (DNP-TEG)3-G3(A3)7G3-(DNP-TEG)3 (f)
C3(T3)7C3 48 4.7 x 10
8 0.6 -44.9 -110.9 -11.9
a Antigen valence and mode of binding based on ITC binding stoichiometry; sense ODN sequence is in 5’ 3’ direction. b f: flexible, r: rigid. c Estimated lengths based
on 3.4 Å per nucleotide of DNA and a random walk model (Baird et al. 2003); DNP-TEG: ~ 22.5 Å; SPACER 9: ~ 12.0 Å; DNP-6C: ~ 10Å. d Mediate binding across
DNP-TEG linkers; see Fig. 3. e N/A: not applicable.f Binding stoichiometry of ligand to antibody.
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Table 2. Effect of Epitope Density and MW of Monovalent Ligands on KA
Ligand a n b KA (M-1) DNP content MW (Da) KA (fold- difference) 
I 2.0 3.9 x 106 1 348.7 1.0 
II 1.8 1.3 x 107 2 453.3 3.3
III 1.8 6.5 x 106 1 8993.0 1.7
a
 Reference ligand is shaded gray.
b
 Binding stoichiometry of ligand to antibody.
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Table 3. Effect of Antigenic Valence, Linker Flexibility, and Inter-Epitope Distance on 
KA
Dependent 
Variable ODNs 
a n b KA (M-1) Linker Flexibility c
Inter-
epitope 
distance 
(Å)e
KA (fold- 
difference) 
III 2.0 6.5 x 106 N/Ad N/A 1.0 Antigenic 
valence IV 1.0 1.5 x 107 N/A N/A 2.3 
VI 0.8 2.6 x 107 rigid N/A 1.0 Linker 
flexibility V 0.8 1.9 x 108 flexible N/A 7.3 
IV 1.0 1.5 x 107 N/A 137 1.0 
V 0.8 1.9 x 108 N/A 111 12.6 
VII 0.9 4.3 x 108 N/A 60 28.7 
Inter-
Epitope 
Distance 
VIII 1.1 1.9 x 108 N/A 48 12.7 
III 1.8 6.5 x 106 N/A N/A 1.0 
V 0.8 1.9 x 108 flexible 111 29.1 
VII 0.9 4.3 x 108 flexible 60 66.2 
Combined 
Effect 
VIII 1.1 1.9 x 108 flexible 48 29.2 
a Reference ligand is shaded gray. 
b Binding stoichiometry of ligand to antibody. 
c Refers to inter-epitope linker. 
d N/A: not applicable. 
e Estimated lengths based on 3.4 _ per nucleotide of DNA and a random walk model (ref. 18); DNP-TEG: 
~ 22.5 Å; DNP-6C:  ~ 10Å; SPACER 9: ~12 Å. 
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Table 4. Effect of Binding Capacity on KA During Multivalent Complexation 
ODNs a n b KA (M-1) Hybridization State c
Linker 
Flexibility d
KA (fold-
difference) 
IV 1.0 1.5 x 107 s.s (flexible) Flexible 1.0 
X 0.6 7.2 x 107 s.s (flexible) Flexible 4.8 
IX 1.1 1.3 x 108 d.s (rigid) Flexible 1.0 
XI 0.6 4.7 x 108 d.s (rigid) Flexible 3.6 
X 0.6 7.2 x 107 s.s (flexible) Flexible 1.0 
XI 0.6 4.7 x 108 d.s (rigid) Flexible 6.5 
a
 Reference ligand is shaded gray.
b
 Binding stoichiometry of ligand to antibody.
c s.s: single stranded; d.s: double stranded 
d Refers to inter-epitope linker. 
CHAPTER III 
 
PHARMACOKINETICS AND BIODISTRIBUTION STUDIES 
 
This chapter is based on the following submitted manuscript: 
Palma E. and Cho M.J. Antibodies as Drug Carriers IV: Intravenous Pharmacokinetics 
and Biodistribution of CpG Oligodeoxynucleotides.  Journal of Controlled Release 
(2006). 
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Abstract 
The intravenous dosing of immunotherapeutic CpG oligodeoxyribonucleotides 
(CpG-ODNs) fails to elicit a therapeutic effect due to the poor systemic pharmacokinetics 
displayed by these ODNs.  To address this problem, we have explored the use of anti-
dinitrophenyl (DNP) IgG antibodies as endogenous drug carriers for DNP-derivatized 
CpG-ODNs in DNP-immunized, tumor-bearing mice.  The rationale behind this approach 
is derived from two established concepts: (i) endogenous monomeric immune complexes 
(ICs) exhibit long circulation half-life, slowed clearance, and limited volume of tissue 
distribution (Rehlaender and Cho, 2001a and b) and (ii) macromolecules, including IgG 
antibodies, passively extravasate and accumulate in solid tumors via the enhanced 
permeability and retention (EPR) effect (Takakura et al., 1990).  To this end, CpG-ODNs 
were derivatized at the 3’ end with DNP to express such epitope in a bivalent (DNP2-
CpG-ODN) or monovalent (DNP-CpG-ODN) manner, tritium labeled, and administered 
intravenously into DNP-immunized mice bearing subcutaneous solid tumors.  At specific 
timepoints, blood and major organs, including solid tumors, were collected, homogenized 
and their ODN content measured via liquid scintillation analysis.  Compared to controls, 
mice treated with DNP-[3H]-CpG-ODN or DNP2-[3H]-CpG-ODN exhibited a 266 and 
108-fold increase in `-phase half-life, 1529 and 746-fold decrease in clearance, and a 13 
and 37-fold decrease in volume of tissue distribution, respectively. Tumor accumulation 
was also increased from <1% injected dose (ID)/g tumor for controls to approximately 30 
% ID/g tumor for DNP- and DNP2-[3H]-CpG-ODN.  Together, these findings suggest 
that the in vivo formation of endogenous monomeric ICs constitutes a valid strategy for 
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the improvement of systemic PK and solid tumor targeting of CpG-ODNs to solid 
tumors. 
 
1. Introduction 
When complexed in monomeric fashion, endogenous IgG has been shown to 
reside in the systemic circulation for prolonged periods of time (Rehlaender and Cho, 
2001 and b).  Therapeutic agents with poor systemic PK could take advantage of this 
property by complexing endogenous IgG in such a manner. This approach requires the 
generation of hapten-specific IgG through active immunization and mono-haptenation of 
the drug to be complexed.  Intravenous (IV) administration of such a drug elicits the 
formation of long-circulating monomeric ICs in situ. As such, this approach offers a 
distinct advantage over classical drug delivery strategies in which the drug carrier is 
produced and loaded exogenously.   
 
In addition to improved systemic half-life, monomeric ICs, by virtue of their large 
molecular weight, also display passive targeting to sites of increased vascular 
permeability such as solid tumors and inflammation sites.  In the case of solid tumors, 
enhanced vascular permeability not only supports macromolecular extravasation but also 
tissue accumulation, a phenomenon known as the EPR effect (Greish et al., 2003).  
Passive tissue macromolecular accumulation however, is a transient and reversible 
process if not complemented by an active targeting process, i.e. tissue/cellular affinity 
(Berk et al., 1997).   In the case of monomeric ICs, the Fc portion of IgG actively targets 
Fc= receptor (Fc=R)-expressing cells often found in the periphery of solid tumors, i.e. 
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dendritic cells (DCs) and tumor–associated macrophages (TAMS) (Gessner et al., 1998;
Sica et al., 2002).  With this in mind, the present investigation evaluates the potential of 
endogenous IgG as systemic delivery vectors for CpG oligodeoxynucleotides (CpG-
ODNs), potent peritumoral DC activators (Verthelyi and Klinman, 2003). 
 
This investigation is further supported by current CpG-ODN therapeutic 
regimens, which due to the poor PK disposition of CpG-ODNs require direct CpG-ODN 
injections into the tumor bed or into the tumor periphery (Heckelsmiller et al., 2002;
Lonsdorf et al., 2003).  This approach, however, restricts CpG-ODN therapy to the 
treatment of easily accessible tumors only.  Similarly, current dosing schedules require 
daily CpG-ODN injections to achieve a favorable therapeutic outcome.  Such 
requirement is thought to arise from the short tissue half-life displayed by locally 
injected, untargeted CpG-ODNs (Noll et al., 2005).  We speculate that monomeric ICs, 
which exhibit active Fc=R targeting to tumor-associated DCs and macrophages, should 
enhance tumor accumulation.  With this working hypothesis, we have evaluated the 
potential of using endogenous anti-DNP IgG to improve the systemic PK and tumor 
accumulation of DNP-derivatized CpG-ODNs in a syngeneic, DNP-immunized mouse 
tumor model.  DNP derivatization at the 3’ end of CpG-ODN is not expected to affect its 
pharmacological activity (Kandimalla et al., 2002).  Accordingly, two DNP-derivatized 
CpG-ODNs were tested: DNP2-CpG-ODN, a bivalent CpG-ODN with enhanced antibody 
binding affinity and DNP-CpG-ODN a monovalent control (Palma et al., 2005).  We 
believe that this approach could potentially reduce the required dose and dosing 
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frequency currently used for CpG-ODN therapy as well as broaden its spectrum of 
therapeutic application. 
 
2. Materials and Methods 
2.1 Materials 
Incomplete and complete Freund’s adjuvants, [3H]-water (5 Ci/g) for ODN 
labeling, endotoxin-free water, and inorganic salts and organic reagents used for 
immunoassay, radiolabeling, and tissue homogenization buffer preparation were all 
obtained from Sigma Chemical Co. (St Louis, MO) and used as received.  Reacti-Vials 
also used during radiolabeling were purchased from Pierce Biotechnology (Rockford, 
IL).  Dinitrophenylated keyhole limpet hemocyanin (DNP-KLH) and serum albumin 
(DNP-BSA) were purchased from Calbiochem (San Diego, CA); goat anti-mouse IgG-
peroxidase conjugate was obtained from Southern Biotech (Birmingham, AL).  
Immunoassay Nunc Maxisorp 96-well plates were obtained from NalgeNunc 
International (Rochester, NY) and immunoassay developing reagents such as O-
Phenylenediamine dihydrochloride (OPD) and stable peroxidase substrate buffer were 
commercially available from Pierce Biotechnology (Rockford, IL).  The Balb/c-derived 
colon carcinoma CT26 cell line was purchased from American Type Culture Collection 
(ATCC, Manassas, VA).  Cell culture reagents such as Dulbecco’s Modified Eagle’s 
Medium (DMEM), fetal bovine serum, penicillin/streptomycin, trypsin-EDTA, and 
Hank’s Balanced Salt Solution (HBSS) were all obtained from Invitrogen Corporation 
(Carlsbad, CA); cell culture vented flasks were purchased from the Corning Corporation 
(Corning, NY).  Control phosphorothioate CpG-ODNs (ODN1826, see Table 1) were 
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commercially obtained from Coley Pharmaceuticals (Wellesley, MA); DNP-CpG-ODN 
and DNP2-CpG-ODN were custom synthesized with phosphorothioate backbones and 
supplied at >98% purity by MWG Biotechnology Inc. (High Point, NC).  Tissue 
processing reagents such as Ultima Gold liquid scintillation cocktail and Solvable tissue 
solubilizer were obtained from Perkin Elmer (Wellesley, MA).  Ketamine HCl (Ketaved, 
100 mg/ml) used during PK experiments was a kind gift from Dr. Phil Smith at the 
University of North Carolina (UNC) School of Pharmacy.  Finally, Balb/c mice were 
obtained from Jackson Laboratories (Bar Harbor, ME). 
 
2.2 Oligodeoxynucleotide Radiolabeling 
Underivatized and DNP-derivatized CpG-ODNs (see Table 1) were tritium 
labeled following the procedure described by Graham et al. (1993) with slight 
modifications.  Briefly, 9 mg, 1.2 mg, and 1.1 mg of CpG-ODN, DNP2-CpG-ODN, and 
DNP-CpG-ODN respectively were each separately suspended in 200 µL of 50 mM 
phosphate buffer at pH 7.8 containing 0.1 mM EDTA and lyophilized overnight in 
Teflon-lined 1 ml Reacti-Vials using a LABCONCO freeze dry system.  The dry ODNs 
were then resuspended in 200 µL of [3H]-water (5 Ci/g) and incubated for six hours at 
90°C in a silicone oil bath.  After six hours, the samples were lyophilized to dryness to 
remove any unexchanged tritiated water and subsequently resuspended in 0.5 ml water to 
remove any rapidly exchangeable protons.  This was followed by 5 continuous cycles of 
aqueous resuspension and lyophilization.  As a final purification step, each ODN sample 
was purified via size exclusion gel chromatography with G-25 Sephadex micro-spin 
columns (Amersham Biosciences, Piscataway, NJ).  Specific activity was calculated in 
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triplicate by direct scintillation counting of 2 uL-aliquots of ODN aqueous solution of 
known concentrations using a Packard Tri-Carb 2900TR Liquid Scintillation Analyzer. 
 
2.3 Vaccine Preparation  
The primary vaccine was prepared by dissolving 20 mg of DNP-KLH conjugate 
in 10 ml of endotoxin-free water with gentle heating to a final concentration of 2 mg/ml.  
This bright yellow-colored solution was then emulsified with 10 ml of Freund’s complete 
adjuvant with a PowerGen 700 Tissue homogenizer (Fisher Scientific, Pittsburg, PA) just 
prior to vaccination.  The secondary DNP-KLH vaccine was similarly prepared except 
that Freund’s incomplete adjuvant was used. 
 
2.4 Animal Model Development: Active Immunization  
Fifty female Balb/c mice (6-8 weeks old, 18-20 grams) were immunized 
intraperitoneally with 200 µL of freshly emulsified primary vaccine (see above).  Mice 
were immunized again two weeks later in the same way with fresh secondary vaccine.  
Blood samples (15-20 µL) were collected into non-heparanized microcapillary tubes by 
tail nicking before primary vaccination to establish antibody background levels and at 6 
weeks post-primary vaccination, just prior to tumor cell inoculation.  Serum was obtained 
by allowing overnight clot formation at 4°C and by cell centrifugation.  Serum samples 
were then 10-fold diluted with 0.5% w/v casein, 0.02% w/v thimerosal 0.1% v/v Tween 
20 in phosphate buffer at pH 7.4 (washing buffer) and stored at -20°C until further 
analysis. 
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Anti-DNP IgG titers were measured by ELISA.  Ninety six-well immunoassay 
plates were coated with 100 µL/well of 10 ng/ml DNP-BSA solution in 0.1 M sodium 
carbonate buffer at pH 9.4 and incubated overnight at 4°C.  Wells were then washed in 
triplicate with 250 µL of washing buffer and blocked with 0.5% w/v casein, 0.02% w/v 
thimerosal in 0.1M phosphate buffer at pH 7.4 (blocking buffer) for 2 hours at room 
temperature (RT).  After washing in triplicate, 50 µL of serially diluted serum samples 
(102-106 at half-log increments) were incubated for 2 hours at RT.  At the end of the 
incubation, wells were again washed in triplicate and incubated with 100 µL of 8000-fold 
diluted goat anti-mouse IgG -peroxidase conjugate for two hours at RT.  Wells were 
washed one last time in triplicate and developed by the addition of 100 µL/well of 1 
mg/ml OPD solution in stable peroxidase substrate buffer.  After 10 minutes of 
incubation at RT, the reaction was stopped by adding 100 µL/well of 1.8 N sulfuric acid.  
Absorbance at 492 nm was measured with a BIORAD 3550 Microplate Reader.  Anti-
DNP IgG titers were determined by fitting absorbance data vs. log (dilution factor) data 
to sigmoidal curves using SigmaPlot version 7.0 (SPSS Inc., Chicago, IL).  Titers were 
derived from the midpoint of each sigmoidal curve as EC50 values, i.e. the effective 
concentration (dilution) necessary to cause a 50% decrease in maximal absorbance. 
 
2.5 Cell Culture and Tumor Cell Inoculation 
Balb/c-derived colon carcinoma CT26 cells were grown to confluency in DMEM 
supplemented with 10% FCS and 1% penicillin/streptomycin.  Six weeks after primary 
vaccination, DNP-immunized mice were subcutaneously inoculated in their right legs 
with 2 x 105 CT26 cells suspended in 100 µL of HBSS.  Tumor cell growth was 
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monitored daily by visual observation for a period of nine days; PK experiments began 
on day 10. 
 
2.6 Pharmacokinetic and Organ Distribution Analysis 
Two series of PK experiments were performed.  The first set of experiments 
investigated the serum PK and tissue distribution of [3H]-CpG-ODN in non-immunized 
CT26 tumor-bearing mice.  The second set of investigations tested the systemic 
disposition of DNP2-[3H]-CpG-ODN and DNP-[3H]-CpG-ODN in DNP-immunized, 
tumor-bearing mice.  [3H]-CpG-ODN was also tested in this animal model but only to 
confirm that DNP-immunization had no effect on the PK on this underivatized ligand.  It 
is important to note that both sets of experiments followed the same protocols with 
respect to solid tumor development and dosing regimens, and that all animal experiments 
followed UNC IACUC-approved protocols. 
 
In the first series of experiments non-immunized, tumor-bearing mice were IV 
dosed via tail vein injections with 2.8 nanomole of [3H]-CpG-ODN in 100 uL of PBS 
(17.8 µg; 1.05 x 106 dpm).  This dose amount was chosen on a target signal to noise ratio 
of 104, since common background levels were found to be in the range of 100-200 dpm.  
At 1.0, 2.5, 5, 10, 20, 35, 60, and 120 minutes post-administration, three mice per 
timepoint were either exsanguinated by decapitation (1.0 and 2.5 minute timepoints) or 
anesthetized intraperitoneally with 100 µL injection of 100 mg/ml ketamine 
hydrochloride and exsanguinated by cardiac puncture.  Collected blood samples (100-200 
uL) were allowed to clot overnight at 4°C; the resulting serum was collected by 
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centrifugation using an IEC Micro-MB Centrifuge and stored at -20°C for further 
analysis. Visceral organs such as the liver, kidneys, lungs, heart, and spleen, as well as 
solid tumor, contralateral muscle tissue and injection sites (tail) were subsequently 
harvested, briefly rinsed and blotted dried on tissue paper, weighed, placed in pre-
weighed scintillation vials, flash frozen in liquid nitrogen, and stored at -80°C until 
analyzed. 
 
In the second series of experiments, also performed in triplicate, DNP-
immunized, tumor bearing mice was IV dosed with 2.8 nanomole of DNP2-[3H]-CpG-
ODN (21.8 µg; 5.3 x 106 dpm) in 100 µL of PBS or with 2.8 nanomole of DNP-[3H]-
CpG-ODN(19.7 µg; 6.2 x 106 dpm) in 100 µL of PBS.  At 0.5, 2, 12, 24, 48, and 72 hours 
post-dosing, three mice per timepoint were anesthetized as described above and 
exsanguinated by cardiac puncture.  Organs and tissues of interest (see above) were 
harvested, processed, and stored as described above.  [3H]-CpG-ODN was also tested in 
this DNP-immunized, tumor mouse model but only to corroborate previous findings from 
the non-immunized animal tumor model.  As such, only two timepoints were tested: 60 
and 120 minutes.  It is important to note that the timepoints in this second investigation 
were changed to account for the expected prolongation of circulation half-life gained 
through immunocomplexation in vivo.
2.7 Organ Homogenization and Liquid Scintillation Analysis 
Organs, previously stored at -80°C, were thawed at RT and homogenized in 1-3 
ml of cold homogenizing buffer (10 mM EDTA, 1 mM `-mercaptoethanol, 100 mM Tris 
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buffer at pH 7.5) with a PowerGen 700 tissue homogenizer.  Next 1-2 ml of Solvable 
tissue solubilizer was added to each scintillation vial and heated to 60°C overnight.  
Solubilized organs were decolorized by adding 0.1-0.2 ml of 30% H2O2 and reheating to 
60°C for 2 hours.  Vials were then allowed to cool to RT and supplied with 10 ml of 
Ultima Gold scintillation fluid.  Serum samples, by contrast, were counted by the direct 
addition of scintillation fluid to 25 uL of serum.  Sample radioactivity (dpm) was 
measured using a Packard Tri-Carb 2900TR Liquid Scintillation Analyzer and corrected 
for chromophore quenching and background radioactivity.  Organ-associated 
radioactivity values were further corrected for resident blood volumes (Fogler et al.,
1985). 
 
3. Results and Discussion 
3.1 Serum Pharmacokinetics 
Serum radioactivity data (dpm) obtained by liquid scintillation counting was 
converted to serum CpG-ODN concentrations using specific activity values (see Table 1) 
and plotted vs. time in a semi-logarithmic scale (Figure 1).  Concentration vs. time data 
was subsequently fitted to a two-compartment PK model with reversible distribution 
between central and peripheral compartments (k12, k21) and with elimination from the 
central compartment (k10).  Pharmacokinetic parameters, shown on Table 2, were thus 
derived using WinNonLin 5.0.1 (Pharsight Corporation, Cary, NC).    
 
As shown in Figure 1 and Table 2, graphical and numerical data sharply contrast 
the in vivo PK differences between DNP-derivatized and underivatized 
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oligodeoxynucleotides. Significant increases in  systemic half-life, elimination from 
central compartment half-life (k10 half-life), area under the curve (AUC), and mean 
residence time (MRT) were observed for monovalent and bivalent CpG-ODNs, 
respectively (see Table 2).   These increases most likely resulted from the monomeric 
complexation of endogenous IgG, a serum protein known to circulate systemically with a 
half-life of 21 days in humans and mice (Janeway, 2001). 
 
Surprisingly, DNP2-CpG-ODN, a bivalent oligodeoxynucleotide with enhanced in 
vitro antibody binding affinity (Palma et al., 2005), exhibited lesser changes (vs. 
underivatized control) in derived PK parameters than its monovalent counterpart (Table 
2).  This finding was unexpected since binding affinity was assumed to be the parameter 
that ultimately controls IC stability in vivo and, due to its higher affinity, this ODN was 
expected to achieve higher increases in circulatory half-life than DNP-CpG-ODN.  Close 
examination of Figure 1, however, reveals that similar profiles were exhibited by both 
ODNs and that differences were only observed at the terminal 72-hour timepoint.  We 
speculate that this is likely due to a probable, yet unfortunate, experimental error during 
the last collection timepoint resulting in a decrease in serum concentration that ultimately 
accounts for the quantitative differences seen in the derived PK parameters (Table 2).  
The similar serum concentrations observed up to the last collection timepoint can be 
perhaps explained by the high molar excess of anti-DNP IgG in the systemic circulation 
relative to the tested ODNs such that similar quantitative binding resulted for both, 
monovalent and bivalent ODNs. 
 
61
Similarly, significant decreases in total systemic clearance (CL) and volume of 
tissue distribution (V2) were observed for dinitrophenylated CpG-ODNs relative to 
controls.  This is believed to be a direct consequence of the increase in molecular weight 
experienced by dinitrophenylated CpG-ODNs when complexed to anti-DNP IgG.  An 
increase in molecular weight excludes CpG-ODN from renal clearance and paracellular 
extravasation through normal vascular endothelia, effectively restricting its residence to 
the systemic circulation.   
 
Finally, it is worthy to note that because non-immunized, tumor-bearing mice 
were used to collect the CpG-ODN concentration vs. time data, corroborative studies 
were performed in DNP-immunized, tumor bearing mice.  As expected, serum 
concentrations at 60 and 120 minutes post-dosing in DNP-immunized mice are similar to 
those in the non-immunized model.   This observation supports the rapid in vivo 
clearance and equivalent disposition of underivatized CpG-ODN in both animal models 
and establishes that the presence of anti-DNP IgG had no effect on its pharmacokinetic 
disposition. 
 
3.2 Whole Organ Distribution and Tumor Accumulation 
Distinct patterns of tissue distribution for underivatized and dinitrophenylated 
CpG-ODNs were observed in DNP-immunized, tumor-bearing mice.  As shown in Figure 
2A, CpG-ODN typically associates with clearance organs such as the liver and kidneys.  
This result was expected since phosphorothioate oligodeoxynucleotides undergo 
extensive renal clearance and are subject to hepatic metabolism (Crooke et al., 1996;
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Phillips et al., 1997).  This also supports the rapid systemic clearance observed during PK 
parameterization.  Other organs such as the heart, lungs, spleen and solid tumors, in 
particular, show minimal association (<2% ID).  Solid tumor data was further analyzed 
by normalizing radioactivity data for gram of tumor weight thus reflecting actual tumor 
accumulation (Figure 3A).  It is quite evident that CpG-ODN minimally accumulates in 
tumor tissue, a finding that supports the use of local CpG-ODN dosing methods 
(Heckelsmiller et al., 2002). 
 
In contrast, dinitrophenylated CpG-ODNs, demonstrate a different a 
biodistribution pattern.  It was observed that these CpG-ODNs were mainly associated 
with the liver and solid tumor; however significant radioactivity was also found in the 
kidneys and spleen (Figures 2B and 2C).  This pattern of distribution can be attributed to 
increases in half-life and molecular weight brought about by monomeric complexation as 
well as to the expression of an active targeting moiety, the Fc domain of IgG.  Similarly, 
it was observed that, unlike CpG-ODN, dinitrophenylated CpG-ODNs did not exhibit any 
time-dependence with regard to organ-associated radioactivity (Figures 2B and 2C).  This 
could be the result of the prolonged systemic half-life displayed by these CpG-ODNs. 
 
The large extent of liver association displayed by dinitrophenylated CpG-ODNs is 
due to a combination of the liver’s enhanced macromolecular permeability (discontinous 
vascular endothelial lining), large organ size, high perfusion rate, and its harboring of 
FcR-expressing macrophages (Kupffer cells).  Spleen association, albeit much lower, is 
thought to arise from a combination of enhanced macromolecular permeability 
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(discontinous vascular endothelium) and also its high content of Fc=R-expressing cells.  
In the case of the kidneys, renal association is believed to result from the active uptake by 
Brambell receptor (FcRB)-expressing epithelial cells lining the glomeruli and the 
proximal renal tubules but not from actual renal excretion (Haymann et al, 2000 and 
2004; Kobayashi et al, 2002).  Since FcRB processing results in monomeric IC and IgG 
recycling back to the systemic circulation, we speculate that the nature their association 
was transient. 
 
As shown in Figures 2B and 2C, DNP-derivatization resulted in the delivery of a 
high fraction of %ID to solid tumors relative to underivatized CpG-ODN (Figure 2A).  
Normalization of this data (see Figures 3B and 3C) to derive tumor accumulation values 
reveals the high index of accumulation achieved by CpG-ODN loaded monomeric ICs 
(up to 30% ID/gram of tumor). Such high levels were surprising since other EPR-based 
drug carriers attain maximal tumoral levels of 15-20 %ID/gram of tumor (Takakura et al.,
1990).  Direct comparison to other EPR-based drug carriers, however, is not applicable 
due to the longer half-life and high endogenous concentrations of anti-DNP IgG.  
Nonetheless, we speculate that these high tumor concentrations are a result of prolonged 
IC systemic half-life, large MW, the EPR effect exhibited by solid tumors, and 
ultimately, the active targeting of peritumoral Fc=R-expressing cells.   
 
It was also observed that high tumoral concentrations were achieved only one 
hour after administration and did not significantly decrease over time (Figures 3B and 
3C), suggesting that tumoral accumulation is a sustained and constant process.   This 
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sharply contrasts with classical EPR-based drug delivery systems, which show an 
increasing trend over time with an eventual drop in tumoral accumulation.  The reasons 
behind this effect remain to be investigated.  
 
4. Conclusions 
The present study has explicitly shown the potential of endogenous anti-DNP IgG 
to prolong the systemic circulation, slow the clearance, and promote the tumoral 
accumulation of bivalent and monovalent dinitrophenylated CpG-ODNs.  This is thought 
to occur by the formation of long-circulating monomeric ICs, which by virtue of their 
high molecular weight, passively extravasate only into tissues of increased vascular 
permeability, i.e. liver and solid tumors.  Significant differences between high-affinity, 
bivalent DNP2-CpG-ODN and its lower-affinity monovalent counterpart were not 
observed, prompting us to speculate that the 66-fold enhancement in in vitro binding 
affinity observed with the former ligand (Palma et al., 2005) does not significantly 
impact its in vivo disposition likely due to the high molar excess of endogenous anti-DNP 
IgG.  Such a high molar excess predisposes complete binding of both DNP-derivatized 
CpG-ODNs, irrespective of differences in their in vitro binding affinity.  As a result, 
DNP-CpG-ODN will be our ligand of choice in future investigations in which the tumor 
growth inhibition potential of systemically-delivered CpG-ODNs will be evaluated in the 
same animal tumor model. 
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Table 1. Oligodeoxynucleotides used during PK investigations. 
 
Sequence  
Molecular 
weight 
(g/mole) 
Specific 
Activity 
(dpm/µmole) 
CpG-ODN 5’-TCC ATG ACG TTC CTG ACG TT-3’ 6376 3.73 x 108
DNP-CpG-ODN DNP-TEG-3’-CpG-ODN 7044 2.20 x 109
DNP2-CpG-ODN DNP-TEG-SPACER9-CpG-ODN  DNP-TEG--| 7789 1.88 x 10
9
DNP: 2,4 dinitrophenyl, TEG: tetraethylene glycol, SPACER 9: triethylene glycol 
Control CpG-ODN is shaded grey; CpG motifs are underlined. 
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Table 2. Serum PK parameters and fold-difference comparison between dinitrophenylated and control ODNs
CpG-ODN* DNP-CpG-ODN DNP2-CpG-ODN Fold-difference (DNP-vs. CpG-ODN)
Fold-difference (DNP2-
vs. CpG-ODN)
k10 half-life (hr) 0.0960 ± 0.0604 130 ± 62.1 65.3 ± 12.8 1350 680
 half-life (hr) 0.0215 ± 0.00427 0.121 ± 0.200 0.259 ± 0.519 5.63 12.0
 half-life (hr) 0.694 ± 0.745 185 ± 95.8 74.6 ± 15.0 266 108
AUC (hr * µg / ml) 1.46 ± 0.903 2410 ± 1120 1290 ± 214 1650 884
V1 (ml) 1.75 ± 0.131 1.54 ± 0.172 1.60 ± 0.167 0.880 (d 1.14) 0.914 (d 1.09)
V2 (ml) 8.46 ± 6.24 0.657 ± 0.234 0.228 ± 0.194 0.078 (d 12.8) 0.0270 (d 37.0)
Vss (ml) 10.2 ± 6.26 2.20 ± 0.159 1.83 ± 0.103 0.216 (d 4.63) 0.179 (d 5.59)
CL (ml/hr) 12.6 ± 7.85 0.00825 ± 0.00385 0.0170 ± 0.00281 0.000654 (d 1530) 0.00134 (d 746)
MRT (hr) 0.807 ± 0.949 267 ± 138 108 ± 21.6 331 134
* in non-immunized, tumor bearing mice; control ODN is shaded gray.
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Figure 1. Serum concentration as a function of time of [3H]-CpG-ODN in CT26 tumor-
bearing mice and of DNP-[3H]-DNP-CpG and DNP2-[3H]-CpG-ODN in DNP-
immunized, CT26 tumor-bearing mice.  Briefly, 2.8 nanomole (18-22 µg) of the above 
oligodeoxynucleotides were injected as an intravenous bolus via the tail vein.  At specific 
timepoints, mice were exsanguinated by decapitation or cardiac puncture; collected blood 
was processed for serum and counted via liquid scintillation counting.   
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Figure 2.  Time-dependent whole organ association of [3H]-CpG-ODN (A), DNP-[3H]-
CpG-ODN (B), and DNP2-[3H]-CpG-ODN (C) in DNP-immunized, CT26 tumor-bearing 
Balb/c mice. Three mice per timepoint were intravenously injected via the tail vein with 
2.8 nanomole (18-22 µg) of each ODN and organs were collected at the indicated 
timepoints.  Radioactivity was assessed by liquid scintillation counting of the 
homogenized organs. Note time scale differences among unconjugated and DNP-
conjugated ODNs. 
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Figure 3. Time-dependent tumor accumulation of [3H]-CpG-ODN (A), DNP-[3H]-CpG-
ODN (B), and DNP2-[3H]-CpG-ODN (C) in DNP-immunized, CT26 tumor-bearing 
Balb/c mice.  Three mice per timepoint were intravenously injected via the tail vein with 
2.8 nanomole (18-22 µg) of each ODN and organs were collected at the indicated 
timepoints.  Radioactivity was assessed by liquid scintillation counting of homogenized 
tumors and accumulation was determined by normalizing the data per gram of tumor 
weight.  Note time scale differences among unconjugated and DNP-conjugated ODNs. 
CHAPTER IV 
TUMOR GROWTH INHIBITION AND HISTOLOGICAL STUDIES 
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Abstract 
 The following investigation was conducted to establish a pharmacokinetic-
pharmacodynamic (PK-PD) correlation between the observed accumulation of DNP-
CpG-ODN in tumor tissue and tumor growth inhibition.  The same syngeneic, DNP-
immunized, mouse tumor model previously described in Chapter III was used to test two 
negative control treatment groups (n=7-10; PBS and CpG-ODN treatments) and one 
DNP-CpG-ODN-treated test group (n=10).  In addition, a non-immunized control mouse, 
treated with PBS, was also tested as to assess the effect of immunization on tumor growth 
progression. Mice were treated with 3 total daily bolus injections of 15.7 nanomole of the 
respective formulation every five days.  At specific timepoints, liver, spleens, and solid 
tumors were harvested from one mouse from each respective group and their gross 
physiology recorded. Subsequently, each tissue was processed for histological staining 
with hematoxylin-eosin 
 
Significant quantitative and qualitative differences in tumor growth were 
observed among all treatment groups.  Tumor growth inhibition, as assessed by caliper 
measurements, was only observed with DNP-CpG-ODN-treated mice.  Similarly, solid 
tumor physiology and histological staining were significantly different for this treatment 
group when compared to the two negative control groups.  These findings establish a 
significant correlation between the enhanced accumulation of DNP-CpG-ODN in solid 
tumors observed during pharmacokinetic studies and tumor growth inhibition and tumor 
pathology. 
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1. Introduction 
In the previous chapter it was shown that the in situ formation of monomeric 
immune complexes (ICs) between DNP-CpG-ODN and anti-DNP IgG in the systemic 
circulation leads to a marked improvement in CpG-ODN systemic pharmacokinetics 
(PK) and tumor accumulation in a syngeneic, DNP-immunized, mouse tumor model.  
Because these monomeric ICs actively target FcR-expressing, tumor-associated 
dendritic cells and macrophages via their Fc domain, CpG-ODN uptake into these cells 
should be enhanced.  In turn, enhanced CpG-ODN uptake by these cells, which also 
express the Toll-like receptor 9 (TLR9) specific for CpG-ODN (Klinman, 2004), should 
lead to significant inhibition of tumor growth.   
 
With this in mind, the present investigation was designed to assess the ability of 
CpG-ODN monomeric ICs to inhibit the progressive growth of solid tumors and to gauge 
their gross physiological effect on hepatic, splenic, and tumoral tissue.  To this end, DNP-
immunized, tumor bearing mice were intravenously dosed with PBS, or equimolar doses 
of CpG-ODN or DNP-CpG-ODN every five days.  Since the systemic therapeutic dose of 
CpG-ODN has not been determined, a previously validated dose for local therapy in the 
same (non-immunized) animal tumor model was used (Heckelsmiller et al., 2002).  
Dosing frequency however, was based on the previous PK investigation and takes into 
account the prolonged  half-life of CpG-ODN monomeric ICs.  Tumor growth was 
monitored by periodic caliper measurements until tumor volumes exceeded 2000 mm3.
For tissue gross observation and histological studies, livers, spleens, and solid tumors 
were collected from one mouse from each dosing group, 4-5 days after each dose.  It is 
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important to note that in vitro studies testing the cellular uptake of CpG-ODN monomeric 
ICs in freshly harvested tumoral dendritic cells and macrophages are not addressed here 
and will the subject of a future investigation. 
 
2. Materials and Methods 
2.1. Materials 
Balb/c-derived colon carcinoma CT26 cells (ATCC, Manassas, VA) were grown 
in Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 10% fetal calf 
serum (FCS) and 1% penicillin/streptomycin at 37eC, 5% CO2. Twenty eight female 
Balb/c mice (6 weeks of age, 18-20 grams) were purchased from Jackson Laboratories 
(Bar Harbor, ME); mice were 7 weeks of age at the start of active immunization, 13 
weeks during tumor cell inoculations, and 14 weeks of age when experiments began.  
CpG-ODN (ODN1826) was obtained from Coley Pharmaceuticals (Weslelley, MA) at a 
concentration of 27 mg/ml in PBS (0.5 ml).  DNP-CpG-ODN was custom synthesized by 
MWG Biotechnology Inc. (High Point, NC) and supplied lyophilized at >98 purity.  
Neutral phosphate buffered formalin (10%) and reagent-grade ethanol, used during tissue 
fixation and dehydration respectively, were purchased from Fisher Scientific (Hampton, 
NH).  Ketamine HCl (Ketaved, 100 mg/ml) used during PK experiments was a kind gift 
from Dr. Phil Smith from the UNC School of Pharmacy. 
 
2.2. Animal Model Development 
DNP vaccination, anti-DNP IgG monitoring by ELISA, and tumor induction 
experiments were performed as described in Chapter III.  Unlike the previous 
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investigation, ELISA monitoring was performed biweekly starting at week 0, for a period 
of 6 weeks.  All animal experiments were approved by the University of North Carolina 
at Chapel Hill (UNC) Institutional Animal Care and Use Committee. 
 
2.3. Dosing Schedules and Caliper Measurements 
Twenty seven DNP-immunized, CT26 tumor bearing mice were randomly 
distributed into three treatment groups:  PBS (negative control, n=7), CpG-ODN 
(negative control, n=10), and DNP-CpG-ODN (treatment, n=10).  To assess the effect of 
immunization on tumor growth, one mouse was not immunized during model 
development; this mouse was treated with PBS during experimentation.  Mice were 
dosed via their tail vein with an intravenous (IV) bolus of 100 µL PBS, 100 µg (15.7 
nanomole) CpG-ODN in 100 µL PBS, or 110 µg (15.7 nanomole) DNP-CpG-ODN in 
100 µL PBS on days 9, 14, and 19 post-tumor cell inoculation (every five days).  Tumor 
growth was monitored every 2-3 days by measuring tumor lengths and widths with an 
electronic digital caliper.  Tumor volumes were calculated using the standard volume 
formula for an ellipsoid, length x (width)2 x /6, and reported in cubic millimeters.  Mice 
were euthanized when tumor volumes exceeded 2000 mm3.
2.4. Organ Harvesting / Processing and Histological Studies 
Livers, spleens, and solid tumors were harvested for gross observation and 
histological examination.  Organ harvesting (one mouse/dosing timepoint/dosing group) 
was scheduled as follows: 4 days after the first treatment (CpG-ODN and DNP-CpG-
ODN groups only), 5 days after the second treatment (all groups, including the non-
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immunized mouse), and 8 and 15 days after the third treatment (CpG-ODN and DNP-
CpG-ODN groups only).  Briefly, randomly selected mice were anesthetized 
intraperitoneally with 100 µL of ketamine hydrochloride (100 mg/ml) and exsanguinated 
by cardiac puncture.  Livers, spleens, and solid tumors were subsequently collected, 
rinsed with cold PBS, patted dry, and weighed in pre-weighed 20-ml scintillation vials.  
These vials were supplied with 15-20 volumes (with respect to organ weight) of 
phosphate-buffered formalin and allowed to fix for 2 days; tumors, however, were cut in 
half 1 day into this process to facilitate fixative tissue penetration.  After fixation, organs 
and solid tumors were photographed with a Canon Powershot A520 4.0 megapixel digital 
camera, placed in tissue cassettes, rinsed in running tap water for 15 minutes, and 
dehydrated in 70% aqueous ethanol.  Cassettes were stored in this solution until they 
were submitted to the UNC Animal Histopathology Core Facility for further dehydration, 
embedding, microtome sectioning, and hematoxylin/eosin (H&E) staining.  Sections were 
examined with a Nikon Microphot SA upright compound microscope at the UNC 
Michael Hooker Microscopy Facility. 
 
2.5. Statistics 
Exact Wilcoxon rank sum test was used for comparing the tumor volumes at one 
day before the third dose for DNP-CpG-ODN vs. CpG-ODN, and CpG-ODN vs. PBS.  
For each comparison, we tested the null hypothesis that two groups have identical 
distributions against the alternative hypothesis that the two distributions differ with 
location (median) shift.  Bonferroni correction for multiple comparisons was used for 
controlling the overall type I error.  We have set the significant level for the entire set of 
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2 comparisons equal to 0.05, then the V level for each comparison equal to 0.025 (0.05/2).  
Exact Kruskal-Wallis Test was used to test if there was any difference in tumor volume 
between the three treatment groups before dose 1 (day 0).  Statistical analyses were 
performed with SAS statistical software, version 9.1, SAS Institute Inc. (Cary, NC) by 
the Biostatistics Shared Resource of the UNC Lineberger Comprehensive Cancer Center. 
 
3.  Results and Discussion 
3.1. Antibody Titer 
Serum anti-DNP IgG levels were determined by bi-weekly ELISA measurements 
as described in Chapter III.  Robust anti-DNP IgG responses were observed at the end of 
the six-week period following active immunization.  Accordingly, anti-DNP IgG serum 
levels rose sharply in the first two weeks following immunization, continued to increase, 
albeit at a slower rate, between weeks 2 and 4, and steadied between weeks 4 and 6 (data 
not shown).  This typical antibody response was expected since routine immunization 
protocols were followed. 
 
3.2. Tumor Growth Inhibition Studies 
This investigation was designed to evaluate the potential of intravenously-
administered DNP-CpG-ODN to inhibit tumor growth in an orthotopic, syngeneic tumor 
animal model.  Since the same animal model was also used for PK and biodistribution 
studies, this investigation is also intended to establish a correlation between our PK 
findings, i.e. long systemic half-life and large extent of tumor accumulation, and tumor 
growth inhibition (PK/PD correlation).  Such correlation, however, was established with 
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a dose and dosing schedule that have not been validated for IV administration.  Instead, a 
dose validated for CpG-ODN local therapy in Balb/c mice with subcutaneous CT26 solid 
tumors was used (Heckelsmiller et al., 2002).  The dosing schedule of every 5 days was 
based on the observed `-half life for DNP-CpG-ODN (t1/2, = 184 hrs; table 3.2) 
 
As shown in Figure 1, differences in tumor volumes were detected only three days 
after the first treatment, as mice treated with DNP-CpG-ODN harbored smaller tumors 
than control mice.  These differences were further magnified with subsequent doses and 
sharply contrast the lack of therapeutic efficacy of intravenously-administered 
underivatized CpG-ODNs.  This therapeutic inefficacy is also supported by the similar 
growth profiles exhibited by saline-treated and CpG-ODN-treated mice.  
 
A closer examination of the tumor growth rate (slope) of DNP-CpG-ODN-treated 
mice gives insight to the duration of the therapeutic effect of this formulation.  A sharp 
rise in tumor volume, similar to CpG-ODN and PBS-treated mice, was seen on day 14, 5 
days after the first dose.  However, growth was inhibited after dose 2 and did not exhibit 
any change throughout the duration of the study.  Such results validate our choice of 
dosing frequency and establish a correlation between the observed half-life and 
accumulation profile of DNP-CpG-ODNs and its anti-tumor therapeutic effect. 
 
In contrast, PBS and CpG-ODN-treated mice displayed a constant and rapid 
growth rate throughout the investigation.  Likewise, the PBS-treated, non-immunized 
control mouse exhibited very rapid tumor growth, seemingly faster than the other 
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controls.  However, this observation, due to lack of statistical power (n=1), can only hint 
to a therapeutic anti-tumor effect resulting from anti-DNP immunization alone.  It was 
also interesting to see a sharp rise in tumor growth in DNP-CpG-ODN-treated mice 5 
days after the third dose, between days 24 and 27.  Since the fourth dose would have been 
administered on day 24, this result suggests that additional dosing is needed for a 
sustained therapeutic effect.  The fourth and subsequent doses were unfortunately not 
administered due to the rapid deterioration (tissue necrosis) of the tail of most mice; this 
resulted from the numerous injection attempts during tail vein dosing. 
 
Statistical treatment of tumor volume data from day 0, prior to dose 1 (see Figure 
2A) indicated that there were no significant differences between all the dosing groups 
with respect to median tumor volumes.  In contrast, statistically significant differences in 
tumor volume median values were found on day 18, just prior to DNP-CpG-ODN dose 3, 
between DNP-CpG-ODN and CpG-ODN formulations (p<0.025, see Figure 2B); such 
differences were not observed between PBS- and CpG-ODN-treated mice (p>0.025).  As 
a measure of sample distribution symmetry, the average tumor volume values were also 
included in Figure 2; these values did not differ greatly from median tumor volume 
values, attesting to the even distribution of the data set. 
 
Lastly, it was interesting to note that only inhibition of tumor growth, and not 
tumor regression, was achieved in this investigation.  This was a rather surprising result 
since complete tumor regression was achieved in pilot studies (data not shown).  
However, in the latter investigation, the average tumor starting size was much smaller 
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than in this investigation (80 mm3 vs. 175 mm3, see Figure 2A) suggesting the 
importance of early intervention with this immunotherapeutic approach. Nevertheless, the 
results obtained during this investigation support the further development of DNP-CpG-
ODN as systemic therapy for solid tumors in DNP-immunized subjects. 
 
3.3 Gross Physiology and Histological Studies 
 To gain insight to the organ-level physiological events mediating the anti-tumor 
immunotherapeutic effect of systemically delivered DNP-CpG-ODNs, solid tumors, 
livers, and spleens were harvested at different timepoints after each dose (see section 
2.4).  The liver and the spleen were particularly selected because they show preferential 
accumulation of DNP-CpG-ODNs during biodistribution studies (Chapter III) and are 
key lymphoid organs.  As such, livers, spleens, and solid tumors from all the treatment 
groups, harvested five days after the second dose, are shown on Figure 3.   
 
Liver size and hepatic gross physiology appear unaltered for all the treatment 
groups; however it was observed that, unlike the non-immunized control, DNP-
immunized mice exhibited sections of a whitish tissue (Figure 3A).  It is speculated that 
this effect is due to immunization alone since this was not seen in the non-immunized 
control mouse. Likewise, spleens from immunized mice show a white sheath of 
enveloping tissue not observed with the non-immunized control mouse (Figure 3B).  It is 
believed that this is caused by an active proliferation of lymphocytes induced during 
immunization. 
82
It is also apparent from Figure 3B that spleens of mice treated with CpG-ODN or 
DNP-CpG-ODN are enlarged, a phenomenon known as splenomegaly.  This side effect is 
common to CpG-ODN therapy since such treatment leads to immune cell activation and 
splenic hyperactivity (Heikenwalder et al., 2004; Sparwasser et al., 1999).  The larger 
degree of splenomegaly observed with DNP-CpG-ODN treatment than with CpG-ODN 
therapy was not unexpected, since DNP-CpG-ODNs are passively (EPR effect) and 
actively (Fc-receptor mediated endocytosis) targeted to these organs.  However, the 
degree of splenic enlargement observed in this investigation is much smaller than that 
observed with other CpG-ODN dosing regimens (Heikenwalder et al., 2004).  It remains 
to be investigated if this is deleterious to our therapeutic approach.   
 
Shown on Figure 3C are solid tumors harvested 5 days after the second treatment 
for all dosing groups.  Gross observation of these tissues highlight different physiological 
changes brought about by the different tested formulations.  All solid tumors appear 
similar in size, color, and texture except for the DNP-CpG-ODN treated one; this tumor 
is much smaller in size and displays brittle yellowish tissue in its center.  Such gross 
physiology suggests the existence of dead (necrotic) tissue in the middle of the tumor; 
this is subsequently corroborated by our histological studies (Figure 5). 
 
Temporal and dose-dependent changes in tumor gross physiology after CpG-
ODN and DNP-CpG-ODN treatments are shown on Figure 4.  While CpG-ODN-treated 
tumors do not show any change in gross physiology, DNP-CpG-ODN-treated tumors 
show distinct physiological changes with each dose.  Four days after the first treatment 
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(Figure 4A), a longitudinal yellowish band of necrotic tissue is evident.   Such band is 
more enlarged five days after the second treatment (Figure 4B), and constitutes a larger 
portion of the solid tumor.  The third treatment further enhances this effect, as necrotic 
tissue comprises most of the solid tumor (Figure 4C).   
 
Histological confirmation (H&E staining) of our gross physiological observations 
is shown on Figure 5.  Tumor sections are initially shown at 0.75x magnification as an 
attempt to match the light pink-stained necrotic tissue to the yellow tissue found by gross 
observation (Figure 4).   Tumor tissue was then visualized at 20x to closely look at the 
cellular morphology of necrotic vs. viable tissue (tumor margins).  The differences are 
evident: viable marginal cells, seen after the first dose, exhibit the correct hematoxylin-
purplish nuclear staining while necrotic cells, as seen after the second treatment, display 
nuclear staining characteristic of nuclear condensation, or, as seen after the third 
treatment, lack nuclear staining all together (also see Heikenwalder et al., 2004).  By 
comparison, CpG-ODN treated tumors do not show such staining pattern.  H&E staining 
is yet to be performed in hepatic and splenic sections as to assess any potential 
cytotoxicity in these organs. 
 
4.  Conclusions 
Tumor growth inhibition studies were conducted to correlate the pharmacokinetic 
findings described in Chapter III to a therapeutic effect.  Accordingly, DNP-immunized 
CT26 solid tumor-bearing mice were systemically dosed with PBS, CpG-ODN, and 
DNP-CpG-ODN and tumor volumes monitored via caliper measurements.  Results 
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indicate that only DNP-CpG-ODN-treated animals show statistically significant 
differences in tumor volumes (vs. CpG-ODN).  Livers, spleens, and solid tumors from all 
three treatment groups were collected after each dose for gross physiological analysis and 
histological staining.  Livers show unchanged physiology, however, H&E staining for 
potential cellular cytotoxicity remains to be performed.  The spleens of CpG-ODN- and 
DNP-CpG-ODN-treated mice are somewhat enlarged, a common side effect of CpG-
ODN based immunotherapy.  Solid tumors show necrotic progression with time and dose 
number, a result that truly attests to the systemic anti-tumor efficacy of DNP-CpG-ODN 
in DNP-immunized mice. 
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Figure 1. Tumor growth inhibition by systemically administered DNP-CpG-ODN in DNP-immunized, CT26 tumor bearing female
Balb/c mice. Briefly, 27 mice were treated with PBS, CpG-ODN, or DNP-CpG-ODN on day 9 following tumor cell accumulation and
every 5 days thereafter (black arrows). Tumor growth was determined by caliper measurement every 2-3 days and tumor volumes
calculated using the standard volume formula for an ellipsoid.
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Figure 2. Statistical analysis of tumor volumes prior to the first treatment on day 9 post-tumor cell inoculation (A) and 1 day prior to
dose 3 (18 days post-inoculation; B). Median (red +) and average (green X) values for each treatment groups are shown; significant
differences in median values are denoted by p-values < 0.025.
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Figure 3. Gross physiology of livers (A), spleens (B), and solid tumors (C) from PBS non-immunized*, PBS, CpG-ODN, and DNP-
CpG-ODN treated DNP-immunized, CT26 tumor-bearing mice 5 days after the second treatment. Photographs were taken after
fixation in 10% neutrally buffered formalin.*this mouse was not immunized as it was used to assess the effect of immunization on
tumor growth.
CpG-ODN DNP-CpG-ODNPBSPBS (non-immunized)
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Figure 4.  Gross physiology of solid tumors from CpG-ODN and DNP-CpG-ODN treated 
(left to right) DNP-immunized, CT26 tumor-bearing mice 4 days after dose 1 (A), 5 days 
after dose 2 (B), and 8 days after dose 3 (C).  Note the extent of necrosis (yellowish 
tissue) in DNP-CpG-ODN treated mice. 
A
B
C
CpG-ODN DNP-CpG-ODN 
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Figure 5. Hematoxylin / eosin stained tumor sections collected from CpG-ODN and DNP-CpG-ODN treated DNP-immunized, CT26
solid tumor-bearing mice at 4 days after dose 1 (left), 5 days after dose 2 (middle), and 8 days post dose 3 (right). Sections were
viewed with a Nikon Microphot SA upright compound microscope. 20x-magnified sections correspond to the margins between
necrotic and adjacent tissue.
4 days post dose 1 5 days post dose 2 8 days post dose 3
CpG-ODN
(0.75x)
DNP-CpG-
ODN
(0.75x)
DNP-CpG-
ODN
(20x)
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CHAPTER V 
 
OVERALL CONCLUSIONS AND FUTURE STUDIES
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The investigations presented herein have focused on the development of an 
endogenous systemic delivery system for immunostimulatory, anti-neoplastic CpG 
oligodeoxynucleotides (CpG-ODNs).  Our approach consists of the in situ monomeric 
complexation of intravenously-administered dinitrophenyl- (DNP) derivatized CpG-
ODNs to endogenous anti-DNP IgG elicited through active immunization.  Due to the 
long circulation half-life and high molecular weight of monomeric ICs, complexed DNP-
CpG-ODNs passively extravasate through the permeable endothelium of solid tumors and 
accumulate in the tumor periphery, a phenomenon known as the Enhanced Permeability 
and Retention (EPR) effect (Greish et al., 2003).  Once in the tumor periphery, 
monomeric ICs can target, via their Fc domain, Fc=R-expressing dendritic cells and 
macrophages inhabiting this tissue.  Because these cells express the endosomal Toll-like 
receptor 9 (TLR9) specific for CpG-ODN, they represent our cellular target. 
 
This novel approach to systemic CpG-ODN delivery offers three distinct 
advantages over conventional drug delivery systems.  First, the use of an endogenous 
drug carrier avoids any immunogenicity or formulation issues commonly associated with 
exogenous vectors.  Secondly, the combination of passive (EPR effect) and active 
targeting (Fc=R-mediated endocytosis) result in efficient and more specific drug delivery 
to peritumoral dendritic cells and macrophages.  Finally, tumor-associated 
macromolecular transport barriers are avoided by making the aforementioned cells, and 
not cancer cells per se, our therapeutic target.  Taken together, these features represent a 
major improvement over conventional exogenous drug delivery systems. 
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Prior to in vivo studies, model ODNs were dinitrophenylated following various 
DNP-derivatization strategies and tested, via isothermal titration calorimetry, for their 
ability to bind anti-DNP IgG (Chapter II).  This approach was taken to enhance the 
complexation binding affinity of dinitrophenylated CpG-ODNs as to prevent IC systemic 
dissociation.  Maximal monomeric binding affinity (KA) was achieved by derivatizing the 
DNP epitope in a bivalent manner, thus mediating the binding of both antigen-binding 
sites of IgG. Accordingly, this design was used to derivatize CpG-ODNs for 
pharmacokinetic (PK) experiments and subsequent pharmacodynamic (PD) 
investigations in a syngeneic animal tumor model. 
 
Originally, an ex vivo IC formulation approach was taken.  This strategy was used 
due to the abundant availability of monoclonal anti-DNP IgG and the ease of in vitro IC 
formulation.  Monomeric high-affinity ICs between monoclonal anti-DNP IgG and 
DNP2-CpG-ODN were formulated in vitro at a 1.1 to 1 stoichiometric ratio.  When 
injected intravenously into tumor-bearing mice, these high-affinity ICs rapidly and 
unexpectedly dissociated (results not shown).  This observation, along with Van’t Hoff 
binding analysis calculations, prompted us to conclude that although affinity plays an 
important role in immune complexation, the molar IgG:ODN ratio could play an even 
more critical role in in vivo IC stability.  As such, it was hypothesized that an antibody 
molar excess, combined with enhanced binding affinity, could improve IC stability 
dramatically.  However, because the formulation of highly concentrated IgG for immune 
complexation and subsequent in vivo administration constituted a paramount challenge to 
the progression of this research project, it was decided to switch from an ex vivo 
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formulation approach to an in vivo strategy in which active immunization, although a 
time-consuming process, would provide a vast amount of anti-DNP IgG in vivo.
Bivalent DNP2-CpG-ODNs and monovalent DNP-CpG-ODNs, used as low 
binding affinity controls, exhibited similar prolonged systemic half-lives and enhanced 
tumoral accumulation compared to underivatized controls (CpG-ODN) in a DNP-
immunized syngeneic mouse tumor model.  These results effectively proved our 
hypothesis with regard to the importance of antibody molar excess in ensuring in vivo IC 
stability.  These observations, however, do not suggest that binding affinity can be 
disregarded and that any ligand that shows minimal binding affinity can be systemically 
delivered using this approach; binding affinity plays a major role in immune 
complexation and must be above a certain threshold in order for this delivery strategy to 
be optimally applied.  In the presence of a substantial molar excess of IgG, however, 
maximal binding affinity is not required. 
 
Accordingly, the lower-affinity, less expensive, and easier-to-synthesize DNP-
CpG-ODN was used to test whether the observed tumoral accumulation of CpG-ODNs 
could lead to the inhibition of tumor growth in the same mouse tumor model (Chapter 
IV).  Expectedly, enhanced CpG-ODN tumoral accumulation translated to significant 
tumor growth inhibition.  Accumulation also resulted in tissue necrosis as evidenced by 
gross observation and histological staining.  The cells responsible for mediating necrosis, 
however, remain to be identified and are the subject of ongoing immunohistochemical 
studies.   
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It was intriguing, however, to see that tumor necrosis originated at the tumor core 
and not at the tumor periphery.  Such effect was unexpected since a typical CpG-
mediated response would have elicited T-cells to attack the tumor cells in an inwardly 
fashion, i.e., from the point of cellular extravasation at the tumor periphery toward the 
inside of the solid tumor.  Since the opposite was observed, it remains to be investigated 
whether other immunological defense mechanisms played a role in the observed tumor 
growth inhibition.  Given our observations, it is speculated that growth inhibition could 
have resulted from a hypoxic or an anti-vascular effect, processes that would have limited 
oxygen and nutrient supply to the tumor core, resulting in the observed necrotic pattern.  
This will constitute the subject of future investigations. 
 
The results from this investigation have generated much excitement and 
opportunities for further research.  Firstly, research investigations must be conducted to 
address mechanistic aspects regarding the effect of immune complexation on the cellular 
uptake, cytokine secretion, antigen presentation, and lymphocyte recruitment elicited by 
CpG-ODN.   Secondly, a systemic therapeutic dose as well as corresponding antibody 
levels must be validated prior to conducting further in vivo studies.  Once this dose is 
known, further in vivo studies need to be conducted addressing, i) anti-tumor 
immunological memory, ii) specific cellular mediators involved in the anti-tumor 
response, iii) the magnitude of local and systemic CpG-ODN immune stimulation, and 
iv) therapeutic efficacy in a metastatic animal tumor model.  Lastly, these results warrant 
us to investigate the potential of co-delivering tumor-specific antigens and CpG-ODNs as 
a potential anti-cancer therapeutic vaccine approach.  This strategy is supported by 
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various reports of enhanced antigen cross-presentation and tumor immunogenicity 
resulting from the conjugation of CpG-ODNs to tumor-specific antigens (Heit et al., 2004
and Shirota et al., 2001).  All in all, these studies have undoubtedly established the 
potential of using endogenous anti-hapten IgG for the systemic delivery of haptenated 
drugs to solid tumors and should be used as a foundation for continued research. 
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